Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors
Title External Reference Not Available (N/A)
URL https://ckb.jax.org/about/glossaryOfTerms
Abstract Text This reference is often associated with concepts defined in CKB when other references are not available. For example, category variants, non-specific variants, or drugs with limited information.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
131I-TLX-101 131I-TLX-101 0 0
177Lu-FF58 177Lu-FF58 0 1
177Lu-RAD204 177Lu-RAD204 0 0
212Pb-ADVC001 212Pb-ADVC001 0 1
225Ac-PSMA-R2 225Ac-PSMA-R2 0 1
3HP-2827 3HP-2827 0 1
ABBV-101 ABBV-101 0 1
ABBV-151 + Budigalimab ABBV-151 Budigalimab 0 3
ABBV-303 ABBV-303 0 1
ABBV-368 + ABBV-927 + Budigalimab ABBV-368 ABBV-927 Budigalimab 0 1
ABBV-514 ABBV-514 0 1
ABBV-525 ABBV-525 0 1
ABBV-637 ABBV-637 0 1
ABBV-706 ABBV-706 0 1
ABBV-787 ABBV-787 0 1
ABBV-969 ABBV-969 0 0
ABD-3001 ABD-3001 0 1
ABP 206 ABP 206 0 1
ABSK061 ABSK061 0 1
AC176 AC176 0 1
AC699 AC699 0 1
Activated PTCgamma MILs Activated PTCgamma MILs 0 1
ADA-011 ADA-011 0 1
ADRX-0706 ADRX-0706 0 1
AG-270 AG-270 0 1
AGAR T cells AGAR T cells 0 1
AI-061 AI-061 0 1
ALKS 4230 + Pembrolizumab ALKS 4230 Pembrolizumab 0 4
Allogeneic HPV-specific T cells Allogeneic HPV-specific T cells 0 1
AMG 340 AMG 340 0 1
AMG 355 AMG 355 0 1
AMG 596 AMG 596 0 1
AMT-116 AMT-116 0 1
AMT-253 AMT-253 0 1
AMX-500 AMX-500 0 1
ANV419 ANV419 0 3
ARQ 751 ARQ 751 11 1
ART4215 ART4215 0 1
ART6043 ART6043 0 1
ASCA101 ASCA101 0 1
ASP1002 ASP1002 0 1
ASP1012 ASP1012 0 1
ASP1948 ASP1948 0 1
ASP2074 ASP2074 0 1
AST-008 + Pembrolizumab AST-008 Pembrolizumab 0 1
Atezolizumab + Uliledlimab Atezolizumab Uliledlimab 0 1
ATI-2231 ATI-2231 0 1
ATP150 ATP150 0 0
ATP152 ATP152 0 0
Autogene cevumeran + Pembrolizumab Autogene cevumeran Pembrolizumab 0 1
AZD0305 AZD0305 0 1
AZD0901 AZD0901 0 1
AZD3470 AZD3470 0 2
AZD5851 AZD5851 0 1
AZD5863 AZD5863 0 1
AZD8421 AZD8421 0 1
BAY2862789 BAY2862789 0 1
BAY3563254 BAY3563254 0 1
BBI-355 BBI-355 0 1
BEAM-201 BEAM-201 0 1
BG-68501 BG-68501 0 1
BGB-21447 BGB-21447 0 1
BGB-26808 BGB-26808 0 0
BGB-30813 BGB-30813 0 1
BGB-43395 BGB-43395 0 1
BGB-A3055 BGB-A3055 0 1
BGB-B167 BGB-B167 0 0
BI 1821736 BI 1821736 0 1
BI 3706674 BI 3706674 0 1
Biolen Biolen 0 1
BL0020 BL0020 0 1
BLYG8824A BLYG8824A 0 1
BMS-986183 BMS-986183 0 1
BMS-986226 BMS-986226 0 1
BMS-986277 BMS-986277 0 1
BMS-986298 BMS-986298 0 3
BMS-986408 BMS-986408 0 1
BMS-986442 BMS-986442 0 0
BMS-986449 BMS-986449 0 1
BMS-986453 BMS-986453 0 1
BMS-986458 BMS-986458 0 1
BMS-986460 BMS-986460 0 1
BNA035 BNA035 0 1
BNT142 BNT142 0 1
C-TIL051 C-TIL051 0 0
C7R.CD30.CAR-EBVS T-cells C7R.CD30.CAR-EBVS T-cells 0 1
CAL056 mesylate CAL056 mesylate 0 1
CAR.5/IL15-transduced CB-NK cells CAR.5/IL15-transduced CB-NK cells 0 0
CBP-1019 CBP-1019 0 1
CC-96191 CC-96191 0 1
CC-96673 CC-96673 0 1
CD19-CD34 CAR transduced T cells CD19-CD34 CAR transduced T cells 0 1
CD19CAR(2G)-T2A-HER2tG CD19CAR(2G)-T2A-HER2tG 0 0
CD19CAR(2G)-T2A-HER2tG + EGFR806CAR(2G)-EGFRt CD19CAR(2G)-T2A-HER2tG EGFR806CAR(2G)-EGFRt 0 1
CD371-YSNVZIL-18 CAR T cells CD371-YSNVZIL-18 CAR T cells 0 1
Cetuximab + TPST-1120 Cetuximab TPST-1120 0 1
CHM-1101 CHM-1101 0 1
CHS-006 CHS-006 0 0
CLIC-2201 CLIC-2201 0 1
CPI-200 CPI-200 0 1
CPO301 CPO301 0 1
CRD3874 CRD3874 0 1
CVGBM CVGBM 0 1
CX-2051 CX-2051 0 1
Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel Cyclophosphamide EG12014 Epirubicin Paclitaxel 0 1
Cyclophosphamide + NeoVax Cyclophosphamide NeoVax 0 1
CYT-101 CYT-101 0 0
DB-1202 DB-1202 0 1
DCR-STAT3 DCR-STAT3 0 1
DCSZ11 DCSZ11 0 1
Decoy20 Decoy20 0 1
Descartes-15 Descartes-15 0 0
Descartes-25 Descartes-25 0 1
DF6215 DF6215 0 1
DF9001 DF9001 0 1
DK210 DK210 0 1
DO-2 DO-2 0 1
DS-3939a DS-3939a 0 1
DZ-002 DZ-002 0 1
DZD8586 DZD8586 0 1
EBC-129 EBC-129 0 1
EGFR806-specific CAR T cells EGFR806-specific CAR T cells 0 1
EGFR806CAR(2G)-EGFRt EGFR806CAR(2G)-EGFRt 0 1
EIK1001 EIK1001 0 0
EMB-07 EMB-07 0 1
EO2040 EO2040 0 0
ERAS-9 ERAS-9 0 0
ETBX-021 ETBX-021 0 2
Exemestane + GS-5829 Exemestane GS-5829 0 3
FAZ053 FAZ053 0 1
Fluorouracil + Irinotecan + Leucovorin + TRK-950 Fluorouracil Irinotecan Leucovorin TRK-950 0 1
FMPV-1 FMPV-1 0 0
FOG-001 FOG-001 0 1
FT522 FT522 0 0
GEN1056 GEN1056 0 1
GH52 GH52 0 0
GIM-122 GIM-122 0 1
GLB-001 GLB-001 0 1
GRN-1201 GRN-1201 0 0
GS-0201 GS-0201 0 1
GS-4528 GS-4528 0 1
GS-9911 GS-9911 0 1
GSK3745417 + Pembrolizumab GSK3745417 Pembrolizumab 0 1
GSK4524101 GSK4524101 0 1
GV20-0251 GV20-0251 0 1
HB0045 HB0045 0 1
HER2-pulsed DC1 vaccine HER2-pulsed DC1 vaccine 0 8
HF158K1 HF158K1 0 1
HMPL-453 HMPL-453 1 0
HP518 HP518 0 1
HS-110 HS-110 0 1
HTL0039732 HTL0039732 0 1
HTR2 T cells HTR2 T cells 0 1
IACS-6274 + Paclitaxel IACS-6274 Paclitaxel 0 1
IAG933 IAG933 0 1
IBI129 IBI129 0 1
IBI130 IBI130 0 1
IBI133 IBI133 0 1
IBI3003 IBI3003 0 1
IBI3004 IBI3004 0 1
IBI334 IBI334 0 1
iC9.CAR-CSPG4 T cells iC9.CAR-CSPG4 T cells 0 1
IDP-023 IDP-023 0 1
II-11 II-11 0 0
IMA202 IMA202 0 1
IMA401 IMA401 0 1
IMP1734 IMP1734 0 1
IMPT-314 IMPT-314 0 1
IMU-935 IMU-935 0 1
INBRX-106 INBRX-106 0 1
INCB099280 INCB099280 0 3
INCB161734 INCB161734 0 1
IOS-1002 IOS-1002 0 1
IPN01194 IPN01194 0 0
iTCR-transduced PBL iTCR-transduced PBL 0 0
IVAC IVAC 0 1
IVT-8086 IVT-8086 0 0
JNJ-70218902 JNJ-70218902 0 1
JNJ-79032421 JNJ-79032421 0 1
JNJ-79635322 JNJ-79635322 0 1
JNJ-86974680 JNJ-86974680 0 0
JNJ-87189401 JNJ-87189401 0 0
JNJ-87801493 JNJ-87801493 0 0
JNJ-87890387 JNJ-87890387 0 1
JNJ-90009530 JNJ-90009530 0 1
JS009 JS009 0 1
JSKN033 JSKN033 0 1
JV-213 JV-213 0 1
KAZ954 KAZ954 0 1
KB-GDT-01 KB-GDT-01 0 1
KBA1412 KBA1412 0 1
KFA115 KFA115 0 1
KGX101 KGX101 0 1
KITE-718 KITE-718 0 2
KO-2806 KO-2806 0 1
KSQ-001EX KSQ-001EX 0 1
KTX-1001 KTX-1001 0 1
KUR-502 KUR-502 0 1
LAT010 LAT010 0 1
LBS-007 LBS-007 0 1
LEU011 LEU011 0 0
LM-061 LM-061 0 1
LP-168 LP-168 0 1
LSZ 102 LSZ 102 0 1
LVGN6501 LVGN6501 0 0
LY4101174 LY4101174 0 1
LZM009 LZM009 0 1
MBF-362 MBF-362 0 1
MBRC-101 MBRC-101 0 1
MEDI5083 MEDI5083 0 1
MEDI7247 MEDI7247 0 2
MEDI9090 MEDI9090 0 0
MGC026 MGC026 0 0
MHB036C MHB036C 0 1
MHB088C MHB088C 0 1
MK-1088 MK-1088 0 1
MK-1200 MK-1200 0 0
MK-1308 MK-1308 0 1
MK-1308A MK-1308A 0 3
MK-1484 MK-1484 0 1
MK-3475A MK-3475A 0 1
MK-4280A MK-4280A 0 6
MK-4464 MK-4464 0 1
MK-6598 MK-6598 0 1
MPT-0118 MPT-0118 0 1
MQ710 MQ710 0 1
mRNA plus lysate-loaded dendritic cell vaccine mRNA plus lysate-loaded dendritic cell vaccine 0 0
mRNA-2736 mRNA-2736 0 1
MS201408-0005A MS201408-0005A 0 1
MS201408-0005B MS201408-0005B 0 0
MS201408-0005C MS201408-0005C 0 0
MSB2311 MSB2311 0 1
MT-601 MT-601 0 1
NB004 NB004 0 1
NEO-PV-01 NEO-PV-01 0 0
NeoVax NeoVax 0 2
NG101m NG101m 0 0
Nivolumab + Olutasidenib Nivolumab Olutasidenib 0 1
Nivolumab + RP1 Nivolumab RP1 0 1
Nivolumab + SER-401 Nivolumab SER-401 0 1
NKT3447 NKT3447 0 1
NM1F NM1F 0 1
NM6603 NM6603 0 1
NPX887 NPX887 0 0
NT-112 NT-112 0 1
NT-175 NT-175 0 1
NUMARZU-001 NUMARZU-001 0 1
NUV-868 NUV-868 0 1
NXP800 NXP800 0 1
NY-ESO-1 TCR CD4- CD34+ HSC NY-ESO-1 TCR CD4- CD34+ HSC 0 1
NY-ESO-1 TCR/IL-15 NK NY-ESO-1 TCR/IL-15 NK 0 0
Orismilast Orismilast 0 1
OSE-279 OSE-279 0 1
OT-A201 OT-A201 0 1
OTS167PO OTS167PO 0 0
P-CD19CD20-ALLO1 P-CD19CD20-ALLO1 0 1
P30-EPS P30-EPS 0 0
PalloV-CC PalloV-CC 0 1
PAS-004 PAS-004 0 1
Pembrolizumab + XmAb22841 Pembrolizumab XmAb22841 0 1
PEP07 PEP07 0 1
Peptide vaccine IPX Peptide vaccine IPX 0 1
PF-06688992 PF-06688992 0 1
PF-06755990 PF-06755990 0 0
PF-06940434 PF-06940434 0 1
PF-07225570 PF-07225570 0 1
PF-07799544 PF-07799544 0 1
PM54 PM54 0 1
PTT-936 PTT-936 0 0
QEQ278 QEQ278 0 1
RC198 RC198 0 1
REGN4336 REGN4336 0 1
REM-422 REM-422 0 2
RiMO-401 RiMO-401 0 1
RLY-5836 RLY-5836 0 1
RM-007 RM-007 0 0
RM-008 RM-008 0 0
RM-1995 RM-1995 0 1
RNK05047 RNK05047 0 1
RO7296682 RO7296682 0 1
RO7502175 RO7502175 0 1
RO7515629 RO7515629 0 1
RO7566802 RO7566802 0 1
RO7589831 RO7589831 0 1
RO7616789 RO7616789 0 1
RO7656594 RO7656594 0 1
ROSE12 ROSE12 0 1
RP-1664 RP-1664 0 1
S095029 S095029 0 1
SC-CAR4BRAIN SC-CAR4BRAIN 0 1
SDGR5 SDGR5 0 0
SG2501 SG2501 0 1
SGN-CEACAM5C SGN-CEACAM5C 0 1
SHR-2002 SHR-2002 0 0
SIM0237 SIM0237 0 1
SIM1811-03 SIM1811-03 0 1
SIRPant-M SIRPant-M 0 1
SL-901 SL-901 0 1
SNV1521 SNV1521 0 1
SON-1010 SON-1010 0 2
SPH4336 SPH4336 0 1
SPL-108 SPL-108 0 1
SPX-303 SPX-303 0 1
SPYK04 SPYK04 0 1
SQZ-AAC-HPV SQZ-AAC-HPV 0 1
STM-416 STM-416 0 1
SY-2101 SY-2101 0 1
Sym022 Sym022 0 1
Sym023 Sym023 0 1
TAK-280 TAK-280 0 1
TAVT-45 TAVT-45 0 0
TBI-2001 TBI-2001 0 1
TBio-6517 TBio-6517 0 1
TCRT-ESO-A2 TCRT-ESO-A2 0 1
TEIPP24 TEIPP24 0 1
TGN-S11 TGN-S11 0 1
TGRX-678 TGRX-678 0 1
TORL-3-600 TORL-3-600 0 1
TORL-4-500 TORL-4-500 0 1
TP-1454 TP-1454 0 1
TRPH 011 TRPH 011 0 0
TUB-040 TUB-040 0 1
V938 V938 0 0
VSV-GP154 VSV-GP154 0 0
VVD-130037 VVD-130037 0 1
VVD-130850 VVD-130850 0 1
X4P-001 X4P-001 0 1
XmAb808 XmAb808 0 0
ZL-1310 ZL-1310 0 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
131I-TLX-101 Limited information is currently available on 131I-TLX-101 (Mar 2024).
177Lu-FF58 177LuFF58 Limited information is currently available on 177Lu-FF58, a putative radioligand therapy (Dec 2023).
177Lu-RAD204 177Lu RAD204|177LuRAD204 PD-L1/PD-1 antibody 117 Limited information is currently available on 177Lu-RAD204, a putative radiotherapy targeting CD274 (PD-L1) (Mar 2024).
212Pb-ADVC001 Limited information is currently available on 212Pb-ADVC001 (Jul 2023).
225Ac-PSMA-R2 Limited information is currently available on 225Ac-PSMA-R2, a putative radioligand therapy targeting PSMA (Nov 2023).
3HP-2827 3HP 2827|3HP2827 Limited information is currently available on 3HP-2827 (Mar 2024).
ABBV-101 ABBV 101|ABBV101 BTK inhibitor 35 Limited information is currently available on ABBV-101, a putative BTK degrader (Apr 2023).
ABBV-303 ABBV 303|ABBV303 Limited information is currently available on ABBV-303 (Feb 2024).
ABBV-514 ABBV514|ABBV 514 Limited information is currently available on ABBV-514 (Apr 2023).
ABBV-525 ABBV 525|ABBV525 Limited information is currently available on ABBV-525 (Apr 2023).
ABBV-637 ABBV637|ABBV 637 EGFR Inhibitor (Pan) 61 ABBV-637 is a biological agent targeting EGFR, and potentially results in cell killing of EGFR expressing tumor via an undisclosed mechanism (NCI Drug Dictionary).
ABBV-706 ABBV706|ABBV 706 Limited information is currently available on ABBV-706 (Dec 2022).
ABBV-787 ABBV 787|ABBV787 Limited information is currently available on ABBV-787 (Nov 2023).
ABBV-969 ABBV 969|ABBV969 PSMA Antibody 20 Limited information is currently available on ABBV-969, a putative antibody-drug conjugate (ADC) targeting PSMA and STEAP1 (Mar 2024).
ABD-3001 ABD 3001|ABD3001 Limited information is currently available on ABD-3001, a putative inhibitor of ALDH1 and ALDH3 (Dec 2022).
ABP 206 ABP206|ABP-206 Limited information is currently available on ABP 206, a putative Opdivo (nivolumab) biosimilar (Oct 2023).
ABSK061 ABSK-061|ABSK 061 FGFR2 Inhibitor 22 FGFR3 Inhibitor 19 Limited information is currently available on ABSK061, a putative FGFR2/3 inhibitor (Apr 2023).
AC176 AC-176|AC 176|AC0176 Hormone - Anti-androgens 48 Limited information is currently available on AC176, a putative androgen receptor degrader (Feb 2023).
AC699 AC-699|AC 699 Hormone - Anti-estrogens 25 Limited information is currently available on AC699, a putative estrogen receptor degrader (Apr 2023).
ADA-011 ADA 011|ADA011 Immune Checkpoint Inhibitor 147 Limited information is currently available on ADA-011, a putative monoclonal antibody targeting leukocyte immunoglobulin-like receptors B (LILRB) (Feb 2023).
ADRX-0706 ADRX0706|ADRX 0706 Limited information is currently available on ADRX-0706, a putative NECTIN4 antibody-drug conjugate (ADC) (Sep 2023).
AGAR T cells Limited information is currently available on AGAR T cells, a putative GPC3 CAR T cell carrying an inducible Caspase 9 (iC9) and IL15 (Apr 2023).
AI-061 AI 061|AI061 CTLA4 Antibody 29 PD-L1/PD-1 antibody 117 Limited information is currently available on AI-061, a putative coformulation of the anti-PD-1 antibody AI-025 and the anti-CTLA antibody ONC-392 (May 2023).
AMG 340 AMG-340|AMG340|TNB-585|TNB 585 CD3 Antibody 90 PSMA Antibody 20 Limited information is currently available on AMG 340, a putative bispecific antibody targeting PSMA and CD3 (May 2023).
AMG 355 AMG355|AMG-355 CCR8 Antibody 8 Limited information is currently available on AMG 355, a putative CCR8 antibody (Feb 2024).
AMT-116 AMT116|AMT 116 Limited information is currently available on AMT-116, a putative chimeric antigen receptor (CAR) T-cell therapy (Apr 2023).
AMT-253 AMT 253|AMT253 Limited information is currently available on AMT-253, a putative chimeric antigen receptor (CAR) T-cell therapy (Apr 2023).
AMX-500 AMX500|AMX 500|SAR446329|SAR-446329|SAR 446329 Limited information is currently available on AMX-500 (SAR446329) (Sep 2023).
ANV419 ANV 419|ANV-419 ANV419 is a fusion protein comprised of the cytokine IL-2 and an antibody that blocks the CD25 binding site of IL-2, which retains binding to CD122 and may lead to increased proliferation of CD8 T cells and NK cells and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021;9).
ART4215 ART-4215|ART 4215 ART4215 inhibits DNA polymerase theta and prevents DNA damage repair, potentially leading to enhanced sensitivity to DNA damaging agents (NCI Drug Dictionary).
ART6043 ART-6043|ART 6043 Limited information is currently available on ART6043, a putative inhibitor of DNA polymerase theta (Jul 2023).
ASCA101 ASCA-101|ASCA 101 Limited information is currently available on ASCA101 (Mar 2023).
ASP1002 ASP-1002|ASP 1002 Limited information is currently available on ASP1002, a putative bispecific immune cell engager (Apr 2023).
ASP1012 ASP-1012|ASP 1012 Limited information is currently available on ASP1012, a putative oncolytic virus (Jan 2024).
ASP2074 ASP-2074|ASP 2074 Limited information is currently available on ASP2074, a putative bispecific immune cell engager (Apr 2023).
ATI-2231 ATI2231|ATI 2231 Limited information is currently available on ATI-2231, a putative MAPKAPK2 (MK2) inhibitor (Apr 2023).
ATP150 ATP-150|ATP 150 Limited information is currently available on ATP150, a putative therapeutic protein vaccine (May 2023).
ATP152 ATP-152|ATP 152 Limited information is currently available on ATP152, a putative therapeutic protein vaccine (May 2023).
AZD0305 AZD-0305|AZD 0305 Limited information is currently available on AZD0305 (Dec 2023).
AZD0901 AZD-0901|AZD 0901 CLDN18.2 Antibody 18 Limited information is currently available on AZD0901, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Jan 2024).
AZD3470 AZD 3470|AZD-3470 PRMT5 Inhibitor 16 Limited information is currently available on AZD3470, a putative PRMT5 inhibitor (Nov 2023).
AZD5851 AZD-5851|AZD 5851 Limited information is currently available on AZD5851, a putative chimeric antigen receptor (CAR) T-cell therapy targeting GPC3 (Oct 2023).
AZD5863 AZD 5863|AZD-5863 CD3 Antibody 90 CLDN18.2 Antibody 18 Limited information is currently available on AZD5863, a putative bispecific antibody targeting CLDN18.2 and CD3 (Aug 2023).
AZD8421 AZD-8421|AZD 8421 CDK2 Inhibitor 30 Limited information is currently available on AZD8421, a putative CDK2 inhibitor (Jan 2024).
Activated PTCgamma MILs Limited information is currently available on activated PTCgamma MILs (Apr 2023).
Allogeneic HPV-specific T cells Limited information is currently available on Allogeneic HPV-specific T cells (Dec 2023).
BAY2862789 BAY 2862789|BAY-2862789 Limited information is currently available on BAY2862789, a putative DGK-alpha inhibitor (May 2023).
BAY3563254 BAY 3563254|225Ac-PSMA-Trillium Limited information is available on BAY3563254, a putative radioligand therapy targeting PSMA (Jan 2024).
BBI-355 BBI355|BBI 355 CHK1 Inhibitor 17 Limited information is currently available on BBI-355, a putative CHK1 inhibitor (May 2023).
BEAM-201 BEAM 201|BEAM201 Limited information is currently available on BEAM-201, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD7 (Jun 2023).
BG-68501 BG 68501|BG68501 CDK2 Inhibitor 30 Limited information is currently available on BG-68501, a putative CDK2 inhibitor (Mar 2024).
BGB-21447 BGB 21447|BGB21447 BCL2 inhibitor 27 Limited information is currently available on BGB-21447, a putative BCL2 inhibitor (Mar 2024).
BGB-26808 BGB26808|BGB 26808 MAP4K1 Inhibitor 7 Limited information is currently available on BGB-26808, a putative MAP4K1 (HPK1) Inhibitor (Sep 2023).
BGB-30813 BGB 30813|BGB30813 DGKZ Inhibitor 3 Limited information is currently available on BGB-30813, a putative DGKzeta inhibitor (Jun 2023).
BGB-43395 BGB43395|BGB 43395 CDK4 Inhibitor 17 Limited information is currently available on BGB-43395, a putative CDK4 inhibitor (Dec 2023).
BGB-A3055 BGBA3055|BGB A3055 Limited information is currently available on BGB-A3055 (Jul 2023).
BGB-B167 BGB B167|BGBB167 Limited information is currently available on BGB-B167 (Dec 2022).
BI 1821736 BI-1821736|BI1821736 Limited information is currently available on BI 1821736 (Jun 2023).
BI 3706674 BI-3706674|BI3706674 KRAS Inhibitor 15 Limited information is currently available on BI 3706674, a putative KRAS inhibitor (Nov 2023).
BL0020 BL-0020|BL 0020 Limited information is currently available on BL0020 (Oct 2023).
BLYG8824A BLYG 8824A|BLYG-8824A Limited information is currently available on BLYG8824A (Apr 2023).
BMS-986183 BMS986183|BMS 986183 GPC3 Antibody 4 Limited information is currently available on BMS-986183, a putative antibody drug conjugate targeting Glypican-3 (GPC3) (Apr 2023).
BMS-986277 BMS 986277|BMS986277 Limited information is currently available on BMS-986277, a putative oncolytic adenovirus expressing CD80 that is selective for epithelial cells (Apr 2023).
BMS-986298 BMS 986298|BMS986298 Immune Checkpoint Inhibitor 147 Limited information is available on BMS-986298, a putative subcutaneous formulation of nivolumab (Apr 2023).
BMS-986408 BMS 986408|BMS986408 Limited information is currently available on BMS-986408 (Apr 2023).
BMS-986442 BMS 986442|BMS986442 Limited information is currently available on BMS-986442 (Dec 2022).
BMS-986449 BMS 986449|BMS986449 Limited information is currently available on BMS-986449 (Jun 2023).
BMS-986453 BMS986453|BMS 986453 Limited information is currently available on BMS-986453, a putative chimeric antigen receptor (CAR) T-cell therapy targeting TNFRSF17 (BCMA) and GPRC5D (Dec 2023).
BMS-986458 BMS 986458|BMS986458 BCL6 Inhibitor 5 Limited information is currently available on BMS-986458, a putative BCL6 degrader (Oct 2023).
BMS-986460 BMS986460|BMS 986460 Limited information is currently available on BMS-986460 (Oct 2023).
BNA035 BNA-035|BNA 035|HLX35|HLX 35|HLX-35 EGFR Antibody 55 TNFRSF9 Antibody 30 BNA035 is a bi-specific antibody that binds EGFR and 4-1BB, potentially resulting in increased anti-tumor immune response and lysis of tumor cells expressing EGFR (NCI Drug Dictionary).
BNT142 BNT-142|BNT 142 BNT142 consists of an mRNA encoding a bispecific anti-Claudin 6 (CLDN6) and anti-CD3 antibody encapsulated in a lipid nanoparticle, which potentially leads to activation and proliferation of T-lymphocytes and cytotoxic T-lymphocyte mediated cell death of CLDN6-expressing tumor cells (NCI Drug Dictionary).
Biolen Hormone - Anti-androgens 48 Limited information is currently available on Biolen, a putative Casodex (bicalutamide) implant (Apr 2023).
C-TIL051 CTIL051|C TIL051 C-TIL051 are tumor-derived autologous tumor infiltrating lymphocytes (TILs), which induce killing of tumor cells (NCI Drug Dictionary).
C7R.CD30.CAR-EBVS T-cells C7R.CD30.CAR-EBVST cells Limited information is currently available on C7R.CD30.CAR-EBVS T-cells, putative allogeneic T-cells that have been engineered to express constitutive IL7R (C7R) and a chimeric antigen receptor (CAR) targeting TNFRSF8 (CD30) (Feb 2024). 
CAL056 mesylate CAL056 Limited information is currently available on CAL056 mesylate (Apr 2023).
CAR.5/IL15-transduced CB-NK cells Limited information is currently available on CAR.5/IL15-transduced CB-NK cells (Mar 2024).
CBP-1019 CBP 1019|CBP1019 Limited information is currently available on CBP-1019 (Dec 2023).
CC-96191 CC96191|CC 96191 Limited information is currently available on CC-96191 (Apr 2023).
CC-96673 CC 96673|CC96673 Limited information is currently available on CC-96673 (Apr 2023).
CD19-CD34 CAR transduced T cells Limited information is currently available on CD19-CD34 CAR transduced T cells (Apr 2023).
CD19CAR(2G)-T2A-HER2tG Limited information is currently available on CD19CAR(2G)-T2A-HER2tG (Apr 2023).
CD371-YSNVZIL-18 CAR T cells CD371-specific/YSNVz/IL-18 CAR T-cells CD371-YSNVZIL-18 CAR T cells are T-lymphocytes engineered to express IL-18 and a chimeric antigen receptor (CAR) that targets CLEC12A (CD371), which potentially induce increased antitumor immune response and cytotoxicity against CLEC12A (CD371)-expressing tumor cells (NCI Drug Dictionary).
CHM-1101 CHM 1101|CHM1101 Limited information is currently available on CHM-1101, a putative chlorotoxin-containing chimeric antigen receptor T-cell therapy (Apr 2023).
CHS-006 CHS 006|CHS006 TIGIT Antibody 19 Limited information is currently available on CHS-006, a putative anti-TIGIT antibody (Apr 2023).
CLIC-2201 CLIC 2201|CLIC2201 CD22 Immune Cell Therapy 14 Limited information is currently available on CLIC-2201, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD22 (Feb 2024).
CPI-200 CPI200 Limited information is currently available on CPI-200 (Apr 2023).
CPO301 CPO-301|CPO 301 EGFR Antibody 55 Limited information is currently available on CPO301, a putative antibody-drug conjugate (ADC) targeting EGFR (Jul 2023).
CRD3874 CRD 3874|CRD-3874|CRD3874SI|CRD3874-SI STING1 Agonist 19 Limited information is currently available on CRD3874, a putative STING agonist (Sep 2023).
CVGBM Limited information is currently available on CVGBM, a putative mRNA-based cancer vaccine (Jul 2023).
CX-2051 CX2051|CX 2051 Limited information is currently available on CX-2051, a putative EpCAM-targeting antibody-drug conjugate (ADC) (Mar 2024).
CYT-101 CYT101|CYT 101 Limited information is currently available on CYT-101, a putative allogeneic CMV-specific T-cell therapy (Dec 2023).
DB-1202 DB1202|DB 1202 Limited information is currently available on DB-1202 (Apr 2023).
DCR-STAT3 Limited information is currently available on DCR-STAT3 (Oct 2023).
DCSZ11 DCSZ-11|DCSZ 11 Limited information is currently available on DCSZ11, a putative anti-CD93 antibody (Jan 2023).
DF6215 DF-6215|DF 6215 Limited information is currently available on DF6215, a putative modified cytokine (Nov 2023).
DF9001 DF-9001|DF 9001 DF9001 is a tri-specific natural killer cell engager therapy that binds to tumor-expressed EGFR and NK cells, potentially inducing an anti-tumor immune response against EGFR-expressing tumor cells (NCI Drug Dictionary).
DK210 DK-210|DK 210 Limited information is currently available on DK210 (Sep 2023).
DO-2 DO2|DO 2 MET Inhibitor 59 Limited information is currently available on DO-2, a putative MET inhibitor (Apr 2023).
DS-3939a DS3939a|DS 3939a Limited information is currently available on DS-3939a, a putative antibody-drug conjugate (ADC) targeting tumor-associated MUC1 (Aug 2023).
DZ-002 DZ 002|DZ002 Limited information is currently available on DZ-002 (Apr 2023).
DZD8586 DZD-8586|DZD 8586 Limited information is currently available on DZD8586 (Apr 2023).
Decoy20 Decoy-20|Decoy 20 Limited information is currently available on Decoy20, a putative Toll-like receptor (TLR) agonist-based immunotherapy (Dec 2022).
Descartes-15 Descartes 15|Descartes15 Limited information is currently available on Descartes-15, a putative anti-BCMA mRNA chimeric antigen receptor (CAR) T-cell therapy (Mar 2024).
Descartes-25 Descartes 25|Descartes25 Limited information is currently available on Descartes-25, a putative BCMA and IL-12-targeting therapy (Apr 2023).
EBC-129 EBC129|EBC 129 CEACAM5 Antibody 7 CEACAM6 Antibody 3 Limited information is currently available on EBC-129, a putative CEACAM5/6 antibody-drug conjugate (Apr 2023).
EGFR806CAR(2G)-EGFRt EGFR Immune Cell Therapy 3 Limited information is currently available on EGFR806CAR(2G)-EGFRt (Apr 2023).
EIK1001 EIK-1001|EIK 1001 TLR7 Agonist 10 TLR8 Agonist 8 Limited information is currently available on EIK1001, a putative TLR 7/8 co-agonist (Feb 2024).
EMB-07 EMB 07|EMB07 Limited information is currently available on EMB-07, a putative T cell redirecting bispecific antibody targeting CD3 (Dec 2022).
EO2040 EO-2040|EO 2040 Limited information is currently available on EO2040, a putative microbiome-derived peptide vaccine therapy (Apr 2023).
ERAS-9 ERAS 9|ERAS9 SOS1 Inhibitor 11 Limited information is currently available on ERAS-9, a putative SOS1 inhibitor (Apr 2023).
FMPV-1 FMPV 1|FMPV1 TGFBR2 inhibitor 1 Limited information is currently available on FMPV-1, a putative vaccine targeting TGFRB2 frameshift mutations (Dec 2022).
FOG-001 FOG 001|FOG001 CTNNB1 Inhibitor 27 Limited information is currently available on FOG-001, a putative beta-catenin inhibitor (Jun 2023).
FT522 FT-522|FT 522 Limited information is currently available on FT522, a putative iPSC-derived CAR-NK cell based immunotherapy (Nov 2023).
GEN1056 GEN-1056|GEN 1056 Limited information is currently available on GEN1056 (Apr 2023).
GH52 GH-52|GH 52 SOS1 Inhibitor 11 Limited information is currently available on GH52, a putative SOS1 inhibitor (Apr 2023).
GIM-122 GIM122|GIM 122 Limited information is currently available on GIM-122 (Sep 2023).
GLB-001 GLB001|GLB 001|GLB-C183-A-2 Limited information is currently available on GLB-001 (Dec 2023).
GS-0201 GS0201 PARP Inhibitor (Pan) 30 Limited information is currently available on GS-0201, a putative PARP inhibitor (Jan 2024).
GS-4528 GS 4528|GS4528 Limited information is currently available on GS-4528 (Jun 2023).
GS-9911 GS 9911|GS9911 Limited information is currently available on GS-9911, a putative DGKalpha inhibitor (Nov 2023).
GSK4524101 GSK 4524101|GSK-4524101 Limited information is currently available on GSK4524101 (Oct 2023).
GV20-0251 GV20 0251|GV200251 Limited information is currently available on GV20-0251, a putative IGSF8 antibody (May 2023).
HB0045 HB-0045|HB 0045 Limited information is currently available on HB0045 (Jul 2023).
HER2-pulsed DC1 vaccine HER2-pulsed type-1 polarized autologous dendritic cell vaccine HER2 (ERBB2) Vaccine 13 HER2-pulsed DC1 vaccine is a cancer vaccine comprising patient-derived dendritic cells exposed to ERBB2 (HER2)-derived peptides, which potentially enhances anti-tumor immune response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary).
HF158K1 HF-158K1|HF 158K1 Limited information is currently available on HF158K1, a putative ERBB2 (HER2)-targeting immunoliposome containing doxorubicin (Jul 2023).
HP518 HP 518|HP-518 Limited information is currently available on HP518, a putative proteolysis-targeted chimera (PROTAC) targeting the androgen receptor (AR) (Apr 2023).
HS-110 Viagenpumatucel-L|AD100-gp96-Ig-HLA A1 HS-110 (viagenpumatucel-L) is a tumor cell vaccine comprised of irradiated tumor cells expressing recombinant gp96-Ig, which is secreted and induces an immune response to endogenous tumor cells (NCI Drug Dictionary).
HTL0039732 HTL-0039732|HTL 0039732 Limited information is currently available on HTL0039732, a putative EP4 (PTGER4) antagonist (Jul 2023).
HTR2 T cells HTR2 T-Cells HER2 (ERBB2) Immune Cell Therapy 5 Limited information is currently available on HTR2 T cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting ERBB2 (HER2) and TRAIL-R2 (Feb 2024).
IAG933 IAG 933|IAG-933 IAG933 disrupts the interaction between yes-associated protein 1 (YAP) and the transcription factor TEAD, potentially leading to inhibition of YAP/TEAD-dependent gene expression in tumor cell proliferation and survival (NCI Drug Dictionary).
IBI129 IBI 129|IBI-129 CD276 Antibody 10 Limited information is currently available on IBI129, a putative CD276 (B7-H3) antibody-drug conjugate (ADC) (Sep 2023).
IBI130 IBI-130|IBI 130 Limited information is currently available on IBI130 (Jul 2023).
IBI133 IBI-133|IBI 133 Limited information is currently available on IBI133 (Dec 2023).
IBI3003 IBI-3003|IBI 3003 Limited information is currently available on IBI3003, a putative T-cell engager therapy targeting GPRC5D and BCMA (Oct 2023).
IBI3004 Limited information is currently available on IBI3004 (Jan 2024).
IBI334 IBI-334|IBI 334 Limited information is currently available on IBI334 (Apr 2023).
IDP-023 IDP 023|IDP023 Limited information is currently available on IDP-023, a putative natural killer (NK) cell therapy (Nov 2023).
II-11 II11|II 11 PAK1 Inhibitor 11 Limited information is currently available on II-11, a putative PAK1 inhibitor (Apr 2023).
IMA401 IMA-401|IMA 401 Limited information is currently available on IMA401, a putative T-cell engager (TCER) that targets an MAGEA4 and MAGEA8 derived peptide (Apr 2023).
IMP1734 IMP-1734|IMP 1734 PARP-1 Inhibitor 8 Limited information is currently available on IMP1734, a putative PARP1 inhibitor (Feb 2024).
IMPT-314 IMPT 314|IMPT314 Limited information is currently available on IMPT-314, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20 (Apr 2023).
IMU-935 IMU 935|IMU935 Limited information is currently available on IMU-935, a putative inverse agonist of the transcription factor RORgamma truncated (Dec 2022).
INBRX-106 INBRX106|INBRX 106|ES 102|ES-102|ES102 OX40 Antibody 13 INBRX-106 (ES 102) is a hexavalent antibody that binds to the TNFRSF4 (OX40) receptor, resulting in clustering and activation of TNFRSF4 (OX40), and potentially leading to activation of immune response and tumor cell killing (NCI Drug Dictionary).
INCB099280 INCB 099280|INCB-099280 Limited information is currently available on INCB099280 (Apr 2023).
INCB161734 INCB-161734|INCB 161734 Limited information is currently available on INCB161734 (Jan 2024).
IOS-1002 IOS 1002|IOS1002 Limited information is currently available on IOS-1002, a putative therapy targeting the LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 receptors on immune cells (Apr 2023).
IPN01194 IPN-01194|IPN 01194 ERK Inhibitor (pan) 21 Limited information is currently available on IPN01194, a putative ERK1/2 inhibitor (Mar 2024).
IVAC Limited information is currently available on IVAC, a personalized peptide vaccine (June 2023).
IVT-8086 IVT 8086|IVT8086 LImited information is currently available on IVT-8086, a putative anti-SFRP2 (secreted frizzled-related protein 2) antibody (Apr 2023).
JNJ-70218902 JNJ70218902|JNJ 70218902|JNJ-902|JNJ 902|JNJ902 CD3 Antibody 90 JNJ-70218902 is a bispecific antibody targeting TMEFF2-expressing tumor cells and CD3-expressing T-cells, potentially resulting in T-cell-mediated cell death and antitumor activity (NCI Thesaurus, Ann Oncol (2022) 33 (suppl_7): S616-S652).
JNJ-79032421 JNJ 79032421|JNJ79032421 Limited information is currently available on JNJ-79032421, a putative MSLN (mesothelin) targeting agent (Feb 2024).
JNJ-79635322 JNJ 79635322|JNJ79635322 Limited information is currently available on JNJ-79635322 (Apr 2023).
JNJ-86974680 JNJ 86974680|JNJ86974680 Limited information is currently available on JNJ-86974680 (Nov 2023).
JNJ-87189401 JNJ 87189401|JNJ87189401 PSMA Antibody 20 Limited information is currently available on JNJ-87189401, a putative bispecific antibody targeting PSMA and CD28 (Oct 2023).
JNJ-87801493 JNJ 87801493|JNJ87801493 Limited information is currently available on JNJ-87801493 (Dec 2023).
JNJ-87890387 JNJ 87890387|JNJ87890387 CD3 Antibody 90 Limited information is currently available on JNJ-87890387, a putative bispecific antibody targeting ENPP3 and CD3 (Jan 2024).
JNJ-90009530 JNJ 90009530|JNJ90009530 Limited information is currently available on JNJ-90009530, a putative chimeric antigen receptor (CAR) T cell therapy targeting MS4A1 (CD20) (Nov 2023).
JS009 JS-009|JS 009|TAB009|TAB-009|TAB 009 Limited information is currently available on JS009, a putative CD112R antibody (Apr 2023).
JSKN033 JSKN-033|JSKN 033 HER2 (ERBB2) Antibody 72 HER2 (ERBB2) Antibody-Drug Conjugate 27 Limited information is currently available on JSKN033, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) (Jan 2024).
JV-213 JV213|JV 213 Limited information is currently available on JV-213, a putative chimeric antigen receptor therapy targeting CD79B (Apr 2023).
KAZ954 KAZ-954|KAZ 954 Limited information is currently available on KAZ954, a putative monoclonal antibody targeting ectonucleoside triphosphate diphosphohydrolase (Apr 2023).
KB-GDT-01 Deltacel Limited information is available on KB-GDT-01, a putative cell therapy comprising allogeneic gamma delta T-cells (Jan 2024).
KBA1412 KBA-1412|KBA 1412 Limited information is currently available on KBA1412 (Apr 2023).
KFA115 KFA-115|KFA 115|NVP-KFA115|NVPKFA115|NVP KFA115 Limited information is currently available on KFA115 (May 2023).
KGX101 KGX-101|KGX 101 Limited information is currently available on KGX101, a putative modified form of IL12 (Oct 2023).
KO-2806 KO 2806|KO2806 Farnesyltransferase Inhibitor 4 Limited information is currently available on KO-2806, a putative farnesyltransferase inhibitor (Oct 2023).
KSQ-001EX KSQ 001EX|KSQ001EX Limited information is currently available on KSQ-001EX, a putative therapy comprising tumor infiltrating lymphocytes with inactivation of SOCS1 (Feb 2024).
KTX-1001 KTX 1001|KTX1001 Limited information is currently available on KTX-1001, a putative inhibitor of NSD2 (MMSET) (Apr 2023).
KUR-502 KUR 502|KUR502|CMD 502 Limited information is available on KUR-502, a putative cell therapy comprising allogeneic natural killer T-lymohocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023).
LAT010 LAt-010|LAT 010 Limited information is currently available on LAT010, a putative IL-2 based cytokine (Feb 2024).
LBS-007 LBS 007|LBS007 CDC7 Inhibitor 4 Limited information is currently available on LBS-007, a putative CDC7 inhibitor (Apr 2023).
LEU011 Limited information is available on LEU011, a putative autologous chimeric antigen receptor (CAR) T-cell therapy targeting NKG2D ligands (Jan 2024).
LM-061 LM 061|LM061 Limited information is currently available on LM-061 (Apr 2023).
LP-168 LP168|LP 168 Limited information is currently available on LP-168 (Apr 2023).
LVGN6501 LVGN 6501|LVGN-6501 Limited information is currently available on LVGN6501 (Apr 2023).
LY4101174 LY 4101174|LY-4101174 Limited information is currently available on LY4101174, a putative antibody-drug conjugate (ADC) targeting NECTIN4 (Feb 2024).
MBF-362 MBF362|MBF 362 Limited information is currently available on MBF-362, a putative EP4 (PTGER4) antagonist (Jul 2023).
MBRC-101 MBRC 101|MBRC101 Limited information is currently available on MBRC-101, a putative antibody-drug conjugate (ADC) targeting EPHA5 (Sep 2023).
MEDI9090 MEDI 9090|MEDI-9090 Limited information is currently available on MEDI9090 (Apr 2023).
MGC026 MGC-026|MGC 026 Limited information is currently available on MGC026, a putative antibody-drug conjugate (Mar 2024).
MHB036C MHB-036C|MHB 036C Limited information is currently available on MHB036C (Apr 2023).
MHB088C MHB 088C|MHB-088C Limited information is currently available on MHB088C (Apr 2023).
MK-1088 MK1088|MK 1088 Limited information is currently available on MK-1088 (Apr 2023).
MK-1200 MK1200|MK 1200 Limited information is currently available on MK-1200, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Mar 2024).
MK-1308A Pembrolizumab/Quavonlimab|MK1308A|MK 1308A CTLA4 Antibody 29 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 Limited information is currently available on MK-1308A, a coformulation of Pembrolizumab and Quavonlimab (Apr 2023).
MK-1484 MK 1484|MK1484 Limited information is currently available on MK-1484, a putative IL-2 agonist (Apr 2023).
MK-3475A MK 3475A|MK3475A Limited information is currently available on MK-3475A, a putative formulation of Keytruda (pembrolizumab) with MK-5180 (Apr 2023).
MK-4280A MK4280A|MK 4280A Immune Checkpoint Inhibitor 147 LAG3 Antibody 18 PD-L1/PD-1 antibody 117 Limited information is currently available on MK-4280A, a coformulation of MK-4280 and Pembrolizumab (Dec 2022).
MK-4464 MK4464|MK 4464 Limited information is currently available on MK-4464 (Apr 2023).
MK-6598 MK 6598|MK6598 Limited information is currently available on MK-6598 (Apr 2023).
MPT-0118 MPT0118|MPT 0118 MPT-0118 inhibits mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which may result in reprogramming of regulatory T cells, potentially leading to inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021; Vol 9, Issue Suppl 2; Annals of Oncology 32 (2021): S857).
MQ710 MQ-710|MQ 710 Limited information is currently available on MQ710 (May 2023).
MS201408-0005A Limited information is currently available on MS201408-0005A (Apr 2023).
MS201408-0005B Limited information is currently available on MS201408-0005B (Apr 2023).
MS201408-0005C Limited information is currently available on MS201408-0005C (Apr 2023).
MT-601 MT 601|MT601 Limited information is currently available on MT-601, a putative T-cell therapy targeting 6 tumor-associated antigens (Apr 2023).
NB004 NB 004|NB-004 Limited information is currently available on NB004 (Apr 2023).
NG101m Limited information is currently available on NG101m (Apr 2023).
NKT3447 NKT-3447|NKT 3447 CDK2 Inhibitor 30 Limited information is currently available on NKT3447, a putative CDK2 inhibitor (Mar 2024).
NM1F NM 1F|NM-1F Limited information is currently available on NM1F, a putative anti-PVRIG antibody (May 2023).
NM6603 NM 6603|NM-6603 Limited information is currently available on NM6603 (Oct 2023).
NPX887 NPX-887|NPX 887 Limited information is currently available on NPX887, a putative monoclonal antibody targeting HHLA2 (B7-H7) (Feb 2024).
NT-112 NT112|NT 112 Limited information is currently available on NT-112, a putative T-cell receptor (TCR) therapy targeting KRAS G12D (Feb 2024).
NT-175 NT175|NT 175 Limited information is currently available on NT-175, a putative TP53 R175H-targeted T-cell therapy (Jun 2023).
NUMARZU-001 NUMARZU001|NUMARZU 001 Limited information is currently available on NUMARZU-001, a putative cell therapy comprised of PD-1 (PDCD1)-positive tumor infiltrating lymphocytes (Apr 2023).
NUV-868 NUV868|NUV 868 BET Inhibitor (Pan) 32 NUV-868 selectively binds to the BD2 domain of the BRD4 protein, leading to disruption of chromatin remodeling and decreased expression of oncogenes, potentially leading to growth inhibition of tumor cells (NCI Drug Dictionary).
NXP800 NXP-800|NXP 800 NXP800 is an inhibitor of the HSF1 pathway, with potential antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr ND08).
NY-ESO-1 TCR CD4- CD34+ HSC NY-ESO-1 CD4-TCR CD34+ HSC Limited information is currently available on NY-ESO-1 TCR CD4- CD34+ HSC (Apr 2023).
NY-ESO-1 TCR/IL-15 NK Limited information is currently available on NY-ESO-1 TCR/IL-15 NK, a putative natural killer cell therapy targeting NY-ESO-1 (Oct 2023).
NeoVax Limited information is currently available on NeoVax, a putative peptide personalized tumor vaccine (Apr 2023).
OSE-279 OSE279|OSE 279 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 Limited information is currently available on OSE-279, a putative monoclonal antibody targeting PDCD1 (PD-1) (Apr 2023).
OT-A201 OT A201|OTA201 Limited information is currently available on OT-A201 (Jul 2023).
OTS167PO OTS 167PO|OTS-167PO Limited information is currently available on OTS167PO, a putative MELK inhibitor (Apr 2023).
Orismilast IBI354|IBI-354|IBI 354 Limited information is currently available on Orismilast, a putative PDE4 inhibitor (Dec 2022).
P-CD19CD20-ALLO1 Limited information is currently available on P-CD19CD20-ALLO1, a putative allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20 (Aug 2023).
P30-EPS P30EPS|P30 EPS P30-EPS is a peptide vaccine that consist of EphA2, survivin and cytomegalovirus matrix protein pp65 linked to tetanus toxoid epitope P30, which may lead to a cytotoxic T-lymphocyte mediated response against EphA2, CMV pp65 and survivin-expressing tumor cells (NCI Drug Dictionary).
PAS-004 PAS004|PAS 004|CIP-137401|CIP-1374 MEK1 Inhibitor 26 MEK2 Inhibitor 24 Limited information is currently available on PAS-004, a putative MEK1/2 inhibitor (Mar 2024).
PEP07 PEP-07|PEP 07 CHK1 Inhibitor 17 Limited information is currently available on PEP07, a putative checkpoint kinase 1 (CHK1) inhibitor (Apr 2023).
PF-06940434 PF06940434|PF 06940434 PF-06940434 is an integrin alpha v beta 8 antagonist that prevents the activation of TGFB1, leading to an anti-tumor response (Mar 2020).
PF-07225570 PF07225570|PF 07225570 Limited information is currently available on PF-07225570 (Apr 2023).
PF-07799544 PF 07799544|PF07799544 Limited information is currently available on PF-07799544 (Dec 2022).
PM54 PM-54|PM 54 Limited information is currently available on PM54, a putative trabectedin analog (Dec 2023).
PTT-936 PTT 936|PTT936 Limited information is currently available on PTT-936, a putative ALPK1 activator (Mar 2024).
PalloV-CC Limited information is currently available on PalloV-CC, a putative cancer vaccine (Apr 2023).
Peptide vaccine IPX Limited information is currently available on Peptide vaccine IPX, a putative personalized peptide vaccine (Nov 2023).
QEQ278 QEQ 278|QEQ-278 Limited information is currently available on QEQ278 (Jan 2023).
RC198 RC-198|RC 198 Limited information is currently available on RC198 (Jun 2023).
REGN4336 REGN-4336|REGN 4336 CD3 Antibody 90 PSMA Antibody 20 REGN4336 is a a bispecific antibody that targets prostate-specific membrane antigen (PSMA) expressed on tumor cells and the CD3 antigen expressed on T-lymphocytes, potentially leading to activation and recruitment of cytotoxic T-lymphocytes (CTL) to tumor cells expressing PSMA and CTL-mediated tumor cell killing (NCI Drug Dictionary).
REM-422 REM 422|REM422 Limited information is currently available on REM-422, a putative mRNA degrader targeting MYB (Nov 2023).
RLY-5836 RLY 5836|RLY5836 PIK3CA inhibitor 23 Limited information is currently available on RLY-5836, a putative mutant-selective PIK3CA inhibitor (Apr 2023).
RM-007 RM007|RM 007 KRAS Inhibitor 15 Limited information is currently available on RM-007, a putative Kras inhibitor (Apr 2023).
RM-008 RM008|RM 008 KRAS Inhibitor 15 Limited information is currently available on RM-008, a putative Kras inhibitor (Apr 2023).
RM-1995 RM 1995|RM1995 RM-1995 is an antibody-dye conjugate comprised of an anti-CD35 monoclonal antibody (Basiliximab) linked to the dye IR700, which may result in activation of the cytotoxic T-lymphocyte mediated antitumor immune response (NCI Drug Dictionary).
RNK05047 RNK-05047|RNK 05047 BRD4 Inhibitor 10 Limited information is currently available on RNK05047, a putative BRD4-selective degrader (Aug 2022).
RO7296682 RO-7296682|RO 7296682 RO7296682 is a monoclonal antibody that recognizes CD25 (IL-2R alpha) on regulatory T lymphocytes (Tregs), potentially leading to Treg depletion and increased anti-tumor immune response (NCI Drug Dictionary)
RO7502175 RO-7502175|RO 7502175 Limited information is currently available on RO7502175 (Apr 2023).
RO7515629 RO 7515629|RO-7515629 Limited information is currently available on RO7515629 (Apr 2023).
RO7566802 RO-7566802|RO 7566802 Limited information is currently available on RO7566802 (Nov 2023).
RO7589831 RO-7589831|RO 7589831 Limited information is currently available on RO7589831 (Oct 2023).
RO7616789 RO 7616789|RO-7616789 Limited information is currently available on RO7616789 (Apr 2023).
RO7656594 RO-7656594|RO 7656594|GDC-2992|GDC2992|GDC 2992 Limited information is currently available on RO7656594 (Apr 2023).
ROSE12 ROSE-12|ROSE 12 Limited information is currently available on ROSE12 (Oct 2023).
RP-1664 RP1664|RP 1664 Limited information is currently available on RP-1664, a putative PLK4 inhibitor (Mar 2024).
RiMO-401 RiMO401|RiMO 401 Limited information is currently available on RiMO-401 (Mar 2024).
S095029 S-095029|S 095029|Sym 025|Sym-025|Sym025 NKG2A Antibody 3 S095029 is a monoclonal antibody that targets natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), which may result in an antitumor immune response mediated by NK cells and cytotoxic T-lymphocytes (NCI Drug Dictionary).
SC-CAR4BRAIN Limited information is currently available on SC-CAR4BRAIN, a putative chimeric antigen receptor (CAR) T-cell therapy targeting B7-H3, EGFR, ERBB2 (HER2), and IL-13-zetakine (Apr 2023).
SDGR5 SOS1 Inhibitor 11 Limited information is currently available on SDGR5, a putative SOS1 inhibitor (Apr 2023).
SG2501 SG-2501|SG 2501 Limited information is currently available on SG2501 (Apr 2023).
SGN-CEACAM5C SAR-445953|SAR4 45953|SAR445953 Limited information is currently available on SGN-CEACAM5C, a putative antibody-drug conjugate (ADC) (Dec 2023).
SHR-2002 SHR2002|SHR 2002 Limited information is currently available on SHR-2002 (Apr 2023).
SIM0237 SIM-0237|SIM 0237 PD-L1/PD-1 antibody 117 Limited information is currently available on SIM0237, a putative CD274 (PD-L1) and IL-15 bispecific antibody (Apr 2023).
SIM1811-03 SIM1811 03|SIM181103|SIM0235|SIM-235 Limited information is currently available on SIM1811-03, a putative monoclonal antibody targeting TNFR2 (Dec 2022).
SIRPant-M SI-101|SIRPantM Limited information is currently available on SIRPant-M, a putative autologous activated macrophage therapy (Aug 2023).
SL-901 SL901|SL 901 PI3K Inhibitor (Pan) 40 Limited information is currently available on SL-901, a putative inhibitor of PI3K alpha and delta, and PIK3C2 beta (Apr 2023).
SNV1521 SNV-1521|SNV 1521 PARP-1 Inhibitor 8 Limited information is currently available on SNV1521, a putative PARP1 inhibitor (Feb 2024).
SON-1010 SON 1010|SON1010 Limited information is currently available on SON-1010, a putative IL-12 fusion construct (Dec 2022).
SPH4336 SPH 4336 CDK4/6 Inhibitor 13 Limited information is currently available on SPH4336, a putative CDK4/6 inhibitor (Dec 2022).
SPX-303 SPX303|SPX 303 PD-L1/PD-1 antibody 117 Limited information is currently available on SPX-303, a putative bispecific antibody targeting LILRB2 and CD274 (PD-L1) (Feb 2024).
SPYK04 SPYK 04|SPYK-04 Limited information is currently available on SPYK04 (Apr 2023).
SQZ-AAC-HPV Engineered AAC Loaded with HPV16 Epitopes SQZ-AAC-HPV is a cell therapy comprised of autologous red blood cells engineered to express tumor-specific antigens (TAA) and human papillomavirus (HPV) type 16 epitopes and carrying a Toll-like receptor (TLR) agonist as an adjuvant, with potential to induce an anti-tumor immune response against HPV16- or TAA-expressing tumor cells (NCI Drug Dictionary).
STM-416 STM 416|STM416 Limited information is currently available on STM-416, a putative immunotherapy (Jul 2023).
SY-2101 SY 2101|SY2101 Limited information is currently available on SY-2101, a putative form of Arsenic Trioxide (Apr 2023).
TAK-280 TAK 280|TAK280|MVC280|MVC-280|MVC 280 Limited information is currently available on TAK-280 (Apr 2023).
TAVT-45 TAVT45|TAVT 45 Hormone - Anti-androgens 48 Limited information is currently available on TAVT-45, a putative alternate formulation of Abiraterone acetate (Apr 2023).
TBI-2001 TBI 2001|TBI2001 Limited information is currently available on TBI-2001, a putative cell therapy comprising T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023).
TBio-6517 RIVAL-01 TBio-6517 is an engineered vaccinia virus that expresses the Flt3 ligand, an antibody targeting CTLA4, and the cytokine IL-12, which may lead to immune activation and increased anti-tumor immune response, and decreased tumor cell proliferation (NCI Drug Dictionary).
TCRT-ESO-A2 Limited information is currently available on TCRT-ESO-A2, a putative T-cell receptor (TCR) cell therapy targeting NY-ESO-1 (Apr 2023).
TEIPP24 LRPAP7-30V-SLP vaccine Limited information is currently available for TEIPP24, a putative synthetic long peptide vaccine (Jan 2024).
TGN-S11 TGN S11|TGNS11 Limited information is currently available on TGN-S11, a putative therapy for HPV-related cancers (Apr 2023).
TGRX-678 TGRX 678|TGRX678 BCR-ABL Inhibitor 31 Limited information is currently available on TGRX-678, a putative BCR-ABL inhibitor (Oct 2023).
TORL-3-600 TORL3-600|TORL 3-600 Limited information is currently available on TORL-3-600 (Jul 2023).
TORL-4-500 TORL 4 500|TORL-4500|TORL4500 Limited information is currently available on TORL-4-500 (Sep 2023).
TP-1454 TP1454|TP 1454 TP-1454 is a pyruvate kinase M2 (PKM2) activator, which may inhibit tumor cell viability and tumor growth, and enhance anti-tumor immune response in combination with other agents (Mol Cancer Ther December 1 2019 (18) (12 Supplement) B080).
TRPH 011 TRPH011|TRPH-011 VEGFR2 Antibody 4 Limited information is currently available on TRPH 011, a putative human bispecific antibody targeting vascular endothelial growth factor receptor 2 (KDR) and tyrosine kinase receptor 2 (Tie2) (c).
TUB-040 TUB040|TUB 040 Limited information is currently available on TUB-040, a putative antibody-drug conjugate (ADC) targeting SLC34A2 (NAPI2B) (Mar 2024).
V938 V 938|V-938 Limited information is currently available on V938 (Apr 2023).
VSV-GP154 VSV GP154|VSVGP154 Limited information is currently available on VSV-GP154, a putative viral vector-based therapeutic (May 2023).
VVD-130037 VVD130037|VVD 130037 Limited information is currently available on VVD-130037 (Aug 2023).
VVD-130850 VVD 130850|VVD130850 STAT3 Inhibitor 26 Limited information is currently available on VVD-130850, a putative STAT3 inhibitor (Jan 2024).
X4P-001 Mavorixafor|X4P-001-IO|AMD-070|AMD-11070|AMD11070 CXCR4 Inhibitor 15 Mavorixafor (X4P-001), is a CXCR4 antagonist, which blocks the binding of CXCL12 to prevent metastasis and may activate cytotoxic T-lymphocytes (PMID: 23538388).
XmAb808 XmAb-808|XmAb 808 CD276 Antibody 10 Limited information is currently available on XmAb808, a putative bispecific antibody targeting B7-H3 (CD276) and CD28 (Apr 2023).
ZL-1310 ZL1310|ZL 1310 Limited information is currently available on ZL-1310, a putative DLL3 antibody-drug conjugate (ADC) (Jan 2024).
iC9.CAR-CSPG4 T cells Limited information is currently available on iC9.CAR-CSPG4 T cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CSPG4 (Nov 2023).
iTCR-transduced PBL Individual Patient TCR-Transduced PBL Limited information is currently available on iTCR-transduced PBL, putative autologous T-lymphocytes engineered to express T-cell receptors against patient-specific neoantigens (Apr 2023).
mRNA plus lysate-loaded dendritic cell vaccine Limited information is currently available on mRNA plus lysate-loaded dendritic cell vaccine, a putative autologous dendritic cell vaccine loaded with mRNA and tumor lysate (Jul 2023).
mRNA-2736 mRNA2736|mRNA 2736 Limited information is currently available on mRNA-2736 (Jul 2023).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
ABL1 act mut unknown gain of function ABL1 act mut indicates that this variant results in a gain of function in the Abl1 protein. However, the specific amino acid change has not been identified.
ABL1 amp none no effect ABL1 amplification indicates an increased number of copies of the ABL1 gene. However, the mechanism causing the increase is unspecified.
ABL1 fusion fusion unknown ABL1 fusion indicates a fusion of the ABL1 gene, but the fusion partner is unknown.
ABL1 inact mut unknown loss of function ABL1 inact mut indicates that this variant results in a loss of function of the Abl1 protein. However, the specific amino acid change has not been identified.
ABL1 mutant unknown unknown ABL1 mutant indicates an unspecified mutation in the ABL1 gene.
ABL1 over exp none no effect ABL1 over exp indicates an over expression of the Abl1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
ABL1 rearrange unknown unknown ABL1 rearrangement indicates an unspecified rearrangement of the ABL1 gene.
ABL1 wild-type none no effect Wild-type ABL1 indicates that no mutation has been detected within the ABL1 gene.
ALK act mut unknown gain of function ALK act mut indicates that this variant results in a gain of function in the Alk protein. However, the specific amino acid change has not been identified.
ALK amp none no effect ALK amplification indicates an increased number of copies of the ALK gene. However, the mechanism causing the increase is unspecified.
ALK del exon2 deletion unknown ALK del exon2 indicates a deletion of exon 2 of the ALK gene.
ALK del exon2-19 deletion unknown ALK del exon2-19 indicates the deletion of exons 2-19 of the ALK gene.
ALK del exon3 deletion unknown ALK del exon3 indicates a deletion of exon 3 of the ALK gene.
ALK F1174X missense unknown ALK F1174X indicates any Alk missense mutation that results in replacement of the phenylalanine (F) at amino acid 1174 by a different amino acid.
ALK F1245X missense unknown ALK F1245X indicates any Alk missense mutation that results in replacement of the phenylalanine (F) at amino acid 1245 by a different amino acid.
ALK fusion fusion unknown ALK fusion indicates a fusion of the ALK gene, but the fusion partner is unknown.
ALK G1202X missense unknown ALK G1202X indicates any ALK missense mutation that results in replacement of the glycine (G) at amino acid 1202 by a different amino acid.
ALK I1171X missense unknown ALK I1171X indicates any Alk missense mutation that results in replacement of the isoleucine (I) at amino acid 1171 by a different amino acid.
ALK inact mut unknown loss of function ALK inact mut indicates that this variant results in a loss of function of the Alk protein. However, the specific amino acid change has not been identified.
ALK L1196X missense unknown ALK L1196X indicates any Alk missense mutation that results in replacement of the leucine (L) at amino acid 1196 by a different amino acid.
ALK L1198X missense unknown ALK L1198X indicates any Alk missense mutation that results in replacement of the leucine (L) at amino acid 1198 by a different amino acid.
ALK mutant unknown unknown ALK mutant indicates an unspecified mutation in the ALK gene.
ALK negative unknown loss of function ALK negative indicates a lack of expression of the ALK mRNA and/or protein.
ALK over exp none no effect ALK over exp indicates an over expression of the Alk protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
ALK positive unknown unknown ALK positive indicates the presence of the ALK gene, mRNA, and/or protein. ALK positive has been used alternatively to refer to presence of an ALK fusion or rearrangement. For related data, refer to ALK fusion or ALK rearrange in CKB.
ALK R1275X missense unknown ALK R1275X indicates any Alk missense mutation that results in replacement of the arginine (R) at amino acid 1275 by a different amino acid.
ALK rearrange unknown unknown ALK rearrangement indicates an unspecified rearrangement of the ALK gene.
ALK V1180X missense unknown ALK V1180X indicates any Alk missense mutation that results in replacement of the valine (V) at amino acid 1180 by a different amino acid.
ALK wild-type none no effect Wild-type ALK indicates that no mutation has been detected within the ALK gene.
APC dec exp none no effect APC dec exp indicates decreased expression of the Apc protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
APC inact mut unknown loss of function APC inact mut indicates that this variant results in a loss of function of the Apc protein. However, the specific amino acid change has not been identified.
APC LOH deletion unknown APC LOH indicates the loss of one parental copy of the APC gene, resulting in loss of heterozygosity.
APC mutant unknown unknown APC mutant indicates an unspecified mutation in the APC gene.
APC wild-type none no effect Wild-type APC indicates that no mutation has been detected within the APC gene.
ARID1A amp none no effect ARID1A amplification indicates an increased number of copies of the ARID1A gene. However, the mechanism causing the increase is unspecified.
ARID1A dec exp none no effect ARID1A dec exp indicates decreased expression of the Arid1a protein. However, the mechanism causing the decreased expression is unspecified.
ARID1A del deletion loss of function ARID1A del indicates a deletion of the ARID1A gene.
ARID1A inact mut unknown loss of function ARID1A inact mut indicates that this variant results in a loss of function of the Arid1a protein. However, the specific amino acid change has not been identified.
ARID1A loss unknown loss of function ARID1A loss indicates loss of the ARID1A gene, mRNA, and protein.
ARID1A mutant unknown unknown ARID1A mutant indicates an unspecified mutation in the ARID1A gene.
ARID1A negative unknown loss of function ARID1A negative indicates a lack of expression of the ARID1A mRNA and/or protein.
ARID1A wild-type none no effect Wild-type ARID1A indicates that no mutation has been detected within the ARID1A gene.
ATM amp none no effect ATM amplification indicates an increased number of copies of the ATM gene. However, the mechanism causing the increase is unspecified.
ATM dec exp none no effect ATM dec exp indicates decreased expression of the Atm protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
ATM del deletion loss of function ATM del indicates a deletion of the ATM gene.
ATM inact mut unknown loss of function ATM inact mut indicates that this variant results in a loss of function of the Atm protein. However, the specific amino acid change has not been identified.
ATM LOH deletion unknown ATM LOH indicates the loss of one parental copy of the ATM gene, resulting in loss of heterozygosity.
ATM loss unknown loss of function ATM loss indicates loss of the ATM gene, mRNA, and protein.
ATM mutant unknown unknown ATM mutant indicates an unspecified mutation in the ATM gene.
ATM negative unknown loss of function ATM negative indicates a lack of expression of the ATM mRNA and/or protein.
ATM over exp none no effect ATM over exp indicates an over expression of the Atm protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
ATM positive unknown unknown ATM positive indicates the presence of the ATM gene, mRNA, and/or protein.
ATM wild-type none no effect Wild-type ATM indicates that no mutation has been detected within the ATM gene.
ATR amp none no effect ATR amplification indicates an increased number of copies of the ATR gene. However, the mechanism causing the increase is unspecified.
ATR dec exp none no effect ATR dec exp indicates decreased expression of the Atr protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
ATR del deletion loss of function ATR del indicates a deletion of the ATR gene.
ATR inact mut unknown loss of function ATR inact mut indicates that this variant results in a loss of function of the Atr protein. However, the specific amino acid change has not been identified.
ATR mutant unknown unknown ATR mutant indicates an unspecified mutation in the ATR gene.
ATR over exp none no effect ATR over exp indicates an over expression of the Atr protein. However, the mechanism causing the over expression is unspecified.
ATR positive unknown unknown ATR positive indicates the presence of ATR gene, mRNA, and/or protein.
ATR wild-type none no effect Wild-type ATR indicates that no mutation has been detected within the ATR gene.
B2M amp none no effect B2M amplification indicates an increased number of copies of the B2M gene. However, the mechanism causing the increase is unspecified.
B2M del deletion loss of function B2M del indicates a deletion of the B2M gene.
B2M inact mut unknown loss of function B2M inact mut indicates that this variant results in a loss of function of the B2m protein. However, the specific amino acid change has not been identified.
B2M LOH deletion unknown B2M LOH indicates the loss of one parental copy of the B2M gene, resulting in loss of heterozygosity.
B2M loss unknown loss of function B2M loss indicates loss of the B2M gene, mRNA, and protein.
B2M mutant unknown unknown B2M mutant indicates an unspecified mutation in the B2M gene.
B2M negative unknown loss of function B2M negative indicates a lack of expression of the B2M mRNA and/or protein.
B2M over exp none no effect B2M over exp indicates an over expression of the B2m protein. However, the mechanism causing the over expression is unspecified.
B2M wild-type none no effect Wild-type B2M indicates that no mutation has been detected within the B2M gene.
BRAF A598X missense unknown BRAF A598X indicates any BRAF missense mutation that results in replacement of the alanine (A) at amino acid 598 by a different amino acid.
BRAF act mut unknown gain of function BRAF act mut indicates that this variant results in a gain of function in the Braf protein. However, the specific amino acid change has not been identified.
BRAF amp none no effect BRAF amplification indicates an increased number of copies of the BRAF gene. However, the mechanism causing the increase is unspecified.
BRAF D594X missense unknown BRAF D594X indicates any BRAF missense mutation that results in replacement of the aspartic acid (D) at amino acid 594 by a different amino acid.
BRAF dec exp none no effect BRAF dec exp indicates decreased expression of the Braf protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
BRAF E586X missense unknown BRAF E586X indicates any BRAF missense mutation that results in replacement of the glutamic acid (E) at amino acid 586 by a different amino acid.
BRAF F595X missense unknown BRAF F595X indicates any BRAF missense mutation that results in replacement of the phenylalanine (F) at amino acid 595 by a different amino acid.
BRAF fusion fusion unknown BRAF fusion indicates a fusion of the BRAF gene, but the fusion partner is unknown.
BRAF G464X missense unknown BRAF G464X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 464 by a different amino acid.
BRAF G466X missense unknown BRAF G466X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 466 by a different amino acid.
BRAF G469X missense unknown BRAF G469X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 469 by a different amino acid.
BRAF G596X missense unknown BRAF G596X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 596 by a different amino acid.
BRAF I463X missense unknown BRAF I463X indicates any BRAF missense mutation that results in replacement of the isoleucine (I) at amino acid 463 by a different amino acid.
BRAF inact mut unknown loss of function BRAF inact mut indicates that this variant results in a loss of function of the Braf protein. However, the specific amino acid change has not been identified.
BRAF K601X missense unknown BRAF K601X indicates any BRAF missense mutation that results in replacement of the lysine (K) at amino acid 601 by a different amino acid.
BRAF L485X missense unknown BRAF L485X indicates any BRAF missense mutation that results in replacement of the leucine (L) at amino acid 485 by a different amino acid.
BRAF L597X missense unknown BRAF L597X indicates any BRAF missense mutation that results in replacement of the leucine (L) at amino acid 597 by a different amino acid.
BRAF loss unknown loss of function BRAF loss indicates loss of the BRAF gene, mRNA, and protein.
BRAF mutant unknown unknown BRAF mutant indicates an unspecified mutation in the BRAF gene.
BRAF N581X missense unknown BRAF N581X indicates any BRAF missense mutation that results in replacement of the asparagine (N) at amino acid 581 by a different amino acid.
BRAF over exp none no effect BRAF over exp indicates an over expression of the Braf protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
BRAF P367X missense unknown BRAF P367X indicates any BRAF missense mutation that results in replacement of the proline (P) at amino acid 367 by a different amino acid.
BRAF Q257X missense unknown BRAF Q257X indicates any BRAF missense mutation that results in replacement of the glutamine (Q) at amino acid 257 by a different amino acid.
BRAF R462X missense unknown BRAF R462X indicates any BRAF missense mutation that results in replacement of the arginine (R) at amino acid 462 by a different amino acid.
BRAF rearrange unknown unknown BRAF rearrangement indicates an unspecified rearrangement of the BRAF gene.
BRAF S467X missense unknown BRAF S467X indicates any BRAF missense mutation that results in replacement of the serine (S) at amino acid 467 by a different amino acid.
BRAF T241X missense unknown BRAF T241X indicates any BRAF missense mutation that results in replacement of the threonine (T) at amino acid 241 by a different amino acid.
BRAF T599X missense unknown BRAF T599X indicates any BRAF missense mutation that results in replacement of the threonine (T) at amino acid 599 by a different amino acid.
BRAF V600X missense unknown BRAF V600X indicates any BRAF missense mutation that results in replacement of the valine (V) at amino acid 600 by a different amino acid. BRAF V600 mutations are hotspot mutations that often result in increased Braf kinase activity (PMID: 15035987).
BRAF wild-type none no effect Wild-type BRAF indicates that no mutation has been detected within the BRAF gene.
CBL act mut unknown gain of function CBL act mut indicates that this variant results in a gain of function in the Cbl protein. However, the specific amino acid change has not been identified.
CBL dec exp none no effect CBL dec exp indicates decreased expression of the Cbl protein. However, the mechanism causing the decreased expression is unspecified.
CBL del deletion loss of function CBL del indicates a deletion of the CBL gene.
CBL exon8 unknown unknown CBL exon 8 indicates an unspecified mutation has occurred in exon 8 of the CBL gene.
CBL exon9 unknown unknown CBL exon 9 indicates an unspecified mutation has occurred in exon 9 of the CBL gene.
CBL inact mut unknown loss of function CBL inact mut indicates that this variant results in a loss of function of the Cbl protein. However, the specific amino acid change has not been identified.
CBL mutant unknown unknown CBL mutant indicates an unspecified mutation in the CBL gene.
CBL wild-type none no effect Wild-type CBL indicates that no mutation has been detected within the CBL gene.
CD274 act mut unknown gain of function CD274 act mut indicates that this variant results in a gain of function in the Cd274 protein
CD274 amp none no effect CD274 amp indicates an increased number of copies of the CD274 gene. However, the mechanism causing the increase is unspecified.
CD274 dec exp none no effect CD274 dec exp indicates decreased expression of the Cd274 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
CD274 inact mut unknown loss of function CD274 inact mut indicates that this variant results in a loss of function of the Cd274 protein. However, the specific amino acid change has not been identified.
CD274 mutant unknown unknown CD274 mutant indicates an unspecified mutation in the CD274 gene.
CD274 negative unknown loss of function CD274 negative indicates a lack of expression of the CD274 mRNA and/or protein.
CD274 over exp none no effect CD274 over exp indicates an over expression of the Cd274 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
CD274 positive unknown unknown CD274 positive indicates the presence of the CD274 (PD-L1) mRNA and/or protein.
CD274 rearrange unknown unknown CD274 rearrange indicates an unspecified rearrangement of the CD274 gene.
CDK12 amp none no effect CDK12 amplification indicates an increased number of copies of the CDK12 gene. However, the mechanism causing the increase is unspecified.
CDK12 dec exp none no effect CDK12 dec exp indicates decreased expression of the Cdk12 protein. However, the mechanism causing the decreased expression is unspecified.
CDK12 del deletion loss of function CDK12 del indicates a deletion of the CDK12 gene.
CDK12 inact mut unknown loss of function CDK12 inact mut indicates that this variant results in a loss of function of the Cdk12 protein. However, the specific amino acid change has not been identified.
CDK12 loss unknown loss of function CDK12 loss indicates loss of the CDK12 gene, mRNA, and protein.
CDK12 mutant unknown unknown CDK12 mutant indicates an unspecified mutation in the CDK12 gene.
CDK12 positive unknown unknown CDK12 positive indicates the presence of the CDK12 gene, mRNA, and/or protein.
CDK12 wild-type none no effect Wild-type CDK12 indicates that no mutation has been detected within the CDK12 gene.
CDKN2A amp none no effect CDKN2A amplification indicates an increased number of copies of the CDKN2A gene. However, the mechanism causing the increase is unspecified.
CDKN2A dec exp none no effect CDKN2A dec exp indicates decreased expression of the Cdkn2a protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
CDKN2A del deletion loss of function CDKN2A del indicates a deletion of the CDKN2A gene.
CDKN2A del exon1-2 deletion unknown CDKN2A del exon1-2 indicates the deletion of exons 1-2 of the CDKN2A gene.
CDKN2A hypermethylation unknown unknown CDKN2A hypermethylation indicates an increased methylation of the CDKN2A gene. However, the mechanism causing the hypermethylation is unspecified.
CDKN2A inact mut unknown loss of function CDKN2A inact mut indicates that this variant results in a loss of function of the Cdkn2a protein. However, the specific amino acid change has not been identified.
CDKN2A LOH deletion unknown CDKN2A LOH indicates the loss of one parental copy of the CDKN2A gene, resulting in loss of heterozygosity.
CDKN2A loss unknown loss of function CDKN2A loss indicates loss of the CDKN2A gene, mRNA and protein.
CDKN2A mutant unknown unknown CDKN2A mutant indicates an unspecified mutation in the CDKN2A gene.
CDKN2A negative unknown loss of function CDKN2A negative indicates a lack of expression of the CDKN2A mRNA and/or protein.
CDKN2A over exp none no effect CDKN2A over exp indicates an over expression of the Cdkn2a protein. However, the mechanism causing the over expression is unspecified.
CDKN2A positive unknown unknown CDKN2A positive indicates the presence of the CDKN2A gene, mRNA, and/or protein.
CDKN2A rearrange unknown unknown CDKN2A rearrange indicates an unspecified rearrangement of the CDKN2A gene.
CDKN2A wild-type none no effect Wild-type CDKN2A indicates that no mutation has been detected within the CDKN2A gene.
CSF3R act mut unknown gain of function CSF3R act mut indicates that this variant results in a gain of function in the Csf3r protein. However, the specific amino acid change has not been identified.
CSF3R inact mut unknown loss of function CSF3R inact mut indicates that this variant results in a loss of function of the Csf3r protein. However, the specific amino acid change has not been identified.
CSF3R mutant unknown unknown CSF3R mutant indicates an unspecified mutation in the CSF3R gene.
CSF3R wild-type none no effect Wild-type CSF3R indicates that no mutation has been detected within the CSF3R gene.
CTNNB1 act mut unknown gain of function CTNNB1 act mut indicates that this variant results in a gain of function in the Ctnnb1 protein. However, the specific amino acid change has not been identified.
CTNNB1 amp none no effect CTNNB1 amplification indicates an increased number of copies of the CTNNB1 gene. However, the mechanism causing the increase is unspecified.
CTNNB1 dec exp none no effect CTNNB1 dec exp indicates decreased expression of the Ctnnb1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
CTNNB1 del exon3-4 deletion unknown CTNNB1 del exon3-4 indicates the deletion of exons 3-4 of the CTNNB1 gene.
CTNNB1 inact mut unknown loss of function CTNNB1 inact mut indicates that this variant results in a loss of function of the Ctnnb1 protein. However, the specific amino acid change has not been identified.
CTNNB1 mutant unknown unknown CTNNB1 mutant indicates an unspecified mutation in the CTNNB1 gene.
CTNNB1 over exp none no effect CTNNB1 over exp indicates an over expression of the Ctnnb1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
CTNNB1 wild-type none no effect Wild-type CTNNB1 indicates that no mutation has been detected within the CTNNB1 gene.
DNMT3A act mut unknown gain of function DNMT3A act mut indicates that this variant results in a gain of function in the Dnmt3a protein. However, the specific amino acid change has not been identified.
DNMT3A amp none no effect DNMT3A amplification indicates an increased number of copies of the DNMT3A gene. However, the mechanism causing the increase is unspecified.
DNMT3A del deletion loss of function DNMT3A del indicates a deletion of the DNMT3A gene.
DNMT3A inact mut unknown loss of function DNMT3A inact mut indicates that this variant results in a loss of function of the Dnmt3a protein. However, the specific amino acid change has not been identified.
DNMT3A loss unknown loss of function DNMT3A loss indicates loss of the DNMT3A gene, mRNA, and protein.
DNMT3A mutant unknown unknown DNMT3A mutant indicates an unspecified mutation in the DNMT3A gene.
DNMT3A over exp none no effect DNMT3A over exp indicates an over expression of the Dnmt3a protein. However, the mechanism causing the over expression is unspecified.
DNMT3A wild-type none no effect Wild-type DNMT3A indicates that no mutation has been detected within the DNMT3A gene.
EML4 fusion fusion unknown EML4 fusion indicates a fusion of the EML4 gene, but the fusion partner is unknown.
EML4 inact mut unknown loss of function EML4 inact mut indicates that this variant results in a loss of function of the Eml4 protein. However, the specific amino acid change has not been identified.
EML4 mutant unknown unknown EML4 mutant indicates an unspecified mutation in the EML4 gene.
EML4 wild-type none no effect Wild-type EML4 indicates that no mutation has been detected within the EML4 gene.
FBXW7 del deletion loss of function FBXW7 del indicates a deletion of the FBXW7 gene.
FBXW7 inact mut unknown loss of function FBXW7 inact mut indicates that this variant results in a loss of function of the Fbxw7 protein. However, the specific amino acid change has not been identified.
FBXW7 loss unknown loss of function FBXW7 loss indicates loss of the Fbxw7 gene, mRNA, and protein.
FBXW7 mutant unknown unknown FBXW7 mutant indicates an unspecified mutation in the FBXW7 gene.
FBXW7 positive unknown unknown FBXW7 positive indicates the presence of the FBXW7 gene, mRNA, and/or protein.
FBXW7 wild-type none no effect Wild-type FBXW7 indicates that no mutation has been detected within the FBXW7 gene.
FGFR1 act mut unknown gain of function FGFR1 act mut indicates that this variant results in a gain of function in the Fgfr1 protein. However, the specific amino acid change has not been identified.
FGFR1 amp none no effect FGFR1 amplification indicates an increased number of copies of the FGFR1 gene. However, the mechanism causing the increase is unspecified.
FGFR1 dec exp none no effect FGFR1 dec exp indicates decreased expression of the Fgfr1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
FGFR1 fusion fusion unknown FGFR1 fusion indicates a fusion of the FGFR1 gene, but the fusion partner is unknown.
FGFR1 inact mut unknown loss of function FGFR1 inact mut indicates that this variant results in a loss of function of the Fgfr1 protein. However, the specific amino acid change has not been identified.
FGFR1 mutant unknown unknown FGFR1 mutant indicates an unspecified mutation in the FGFR1 gene.
FGFR1 over exp none no effect FGFR1 over exp indicates an over expression of the FGFR1 protein. However, the mechanism causing the over expression is unspecified.
FGFR1 positive unknown unknown FGFR1 positive indicates the presence of the FGFR1 gene, mRNA, and/or protein.
FGFR1 rearrange unknown unknown FGFR1 rearrangement indicates an unspecified rearrangement of the FGFR1 gene.
FGFR1 wild-type none no effect Wild-type FGFR1 indicates that no mutation has been detected within the FGFR1 gene.
FGFR2 act mut unknown gain of function FGFR2 act mut indicates that this variant results in a gain of function in the Fgfr2 protein. However, the specific amino acid change has not been identified.
FGFR2 amp none no effect FGFR2 amp indicates an increased number of copies of the FGFR2 gene. However, the mechanism causing the increase is unspecified.
FGFR2 dec exp none no effect FGFR2 dec exp indicates decreased expression of the Fgfr2 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
FGFR2 del exon5 deletion unknown FGFR2 del exon5 indicates a deletion of exon 5 of the FGFR2 gene.
FGFR2 del exon7 deletion unknown FGFR2 del exon7 indicates a deletion of exon 7 of the FGFR2 gene.
FGFR2 exon5 unknown unknown FGFR2 exon 5 indicates an unspecified mutation has occurred in exon 5 of the FGFR2 gene.
FGFR2 exon7 unknown unknown FGFR2 exon 7 indicates an unspecified mutation has occurred in exon 7 of the FGFR2 gene.
FGFR2 fusion fusion unknown FGFR2 fusion indicates a fusion of the FGFR2 gene, but the fusion partner is unknown.
FGFR2 inact mut unknown loss of function FGFR2 inact mut indicates that this variant results in a loss of function of the Fgfr2 protein. However, the specific amino acid change has not been identified.
FGFR2 mutant unknown unknown FGFR2 mutant indicates an unspecified mutation in the FGFR2 gene.
FGFR2 over exp none no effect FGFR2 over exp indicates an over expression of the Fgfr2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
FGFR2 positive unknown unknown FGFR2 positive indicates the presence of the FGFR2 gene, mRNA, and/or protein.
FGFR2 rearrange unknown unknown FGFR2 rearrangement indicates an unspecified rearrangement of the FGFR2 gene.
FGFR2 wild-type none no effect Wild-type FGFR2 indicates that no mutation has been detected within the FGFR2 gene.
FGFR3 act mut unknown gain of function FGFR3 act mut indicates that this variant results in a gain of function in the Fgfr3 protein. However, the specific amino acid change has not been identified.
FGFR3 amp none no effect FGFR3 amp indicates an increased number of copies of the FGFR3 gene. However, the mechanism causing the increase is unspecified.
FGFR3 dec exp none no effect FGFR3 dec exp indicates decreased expression of the Fgfr3 protein. However, the mechanism causing the decreased expression is unspecified.
FGFR3 fusion fusion unknown FGFR3 fusion indicates a fusion of the FGFR3 gene, but the fusion partner is unknown.
FGFR3 inact mut unknown loss of function FGFR3 inact mut indicates that this variant results in a loss of function of the Fgfr3 protein. However, the specific amino acid change has not been identified.
FGFR3 mutant unknown unknown FGFR3 mutant indicates an unspecified mutation in the FGFR3 gene.
FGFR3 over exp none no effect FGFR3 over exp indicates an over expression of the Fgfr3 protein. However, the mechanism causing the over expression is unspecified.
FGFR3 positive unknown unknown FGFR3 positive indicates the presence of the ESR1 gene, mRNA, and/or protein.
FGFR3 rearrange unknown unknown FGFR3 rearrangement indicates an unspecified rearrangement of the FGFR3 gene.
FGFR3 wild-type none no effect Wild-type FGFR3 indicates that no mutation has been detected within the FGFR3 gene.
FLT3 act mut unknown gain of function FLT3 act mut indicates that this variant results in a gain of function in the Flt3 protein. However, the specific amino acid change has not been identified.
FLT3 amp none no effect FLT3 amplification indicates an increased number of copies of the FLT3 gene. However, the mechanism causing the increase is unspecified.
FLT3 exon14 unknown unknown FLT3 exon 14, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 14 of the FLT3 gene.
FLT3 exon15 unknown unknown FLT3 exon 15, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 15 of the FLT3 gene.
FLT3 exon16 unknown unknown FLT3 exon 16, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 16 of the FLT3 gene.
FLT3 exon17 unknown unknown FLT3 exon 17, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 17 of the FLT3 gene.
FLT3 exon18 unknown unknown FLT3 exon 18, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 18 of the FLT3 gene.
FLT3 exon19 unknown unknown FLT3 exon 19, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 19 of the FLT3 gene.
FLT3 exon20 unknown unknown FLT3 exon 20, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 20 of the FLT3 gene.
FLT3 exon21 unknown unknown FLT3 exon 21, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 21 of the FLT3 gene.
FLT3 exon22 unknown unknown FLT3 exon 22, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 22 of the FLT3 gene.
FLT3 exon23 unknown unknown FLT3 exon 23, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 23 of the FLT3 gene.
FLT3 fusion fusion unknown FLT3 fusion indicates a fusion of the FLT3 gene, but the fusion partner is unknown.
FLT3 I836X missense unknown FLT3 I836X indicates any Flt3 missense mutation that results in the replacement of the isoleucine (I) at amino acid 836 by a different amino acid.
FLT3 inact mut unknown loss of function FLT3 inact mut indicates that this variant results in a loss of function of the Flt3 protein. However, the specific amino acid change has not been identified.
FLT3 LOH deletion unknown FLT3 LOH indicates the loss of one parental copy of the FLT3 gene, resulting in loss of heterozygosity.
FLT3 mutant unknown unknown FLT3 mutant indicates an unspecified mutation in the FLT3 gene.
FLT3 over exp none no effect FLT3 over exp indicates an over expression of the Flt3 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
FLT3 positive unknown unknown FLT3 positive indicates the presence of the FLT3 gene, mRNA, and/or protein.
FLT3 rearrange unknown unknown FLT3 rearrangement indicates an unspecified rearrangement of the FLT3 gene.
FLT3 wild-type none no effect Wild-type FLT3 indicates that no mutation has been detected within the FLT3 gene.
HRAS act mut unknown unknown HRAS act mut indicates that the variant results in activation of HRAS downstream signaling. The mechanism causing the activation can include either loss of GTP hydrolysis activity (loss of function) or increased nucleotide exchange rate (gain of function).
HRAS amp none no effect HRAS amplification indicates an increased number of copies of the HRAS gene. However, the mechanism causing the increase is unspecified.
HRAS inact mut unknown loss of function HRAS inact mut indicates that the variant results in failure to activate HRAS downstream signaling. However, the specific amino acid change has not been identified.
HRAS mutant unknown unknown HRAS mutant indicates an unspecified mutation in the HRAS gene.
HRAS over exp none no effect HRAS over exp indicates an over expression of the Hras protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
HRAS positive unknown unknown HRAS positive indicates the presence of the HRAS gene, mRNA, and/or protein.
HRAS wild-type none no effect Wild-type HRAS indicates that no mutation has been detected within the HRAS gene.
IDH1 act mut unknown gain of function IDH1 act mut indicates that this variant results in a gain of function in the Idh1 protein. However, the specific amino acid change has not been identified.
IDH1 amp none no effect IDH1 amp indicates an increased number of copies of the IDH1 gene. However, the mechanism causing the increase is unspecified.
IDH1 del deletion loss of function IDH1 del indicates a deletion of the IDH1 gene.
IDH1 G97X missense unknown IDH1 G97X indicates any Idh1 missense mutation that results in replacement of the glycine (G) at amino acid 97 by a different amino acid.
IDH1 inact mut unknown loss of function IDH1 inact mut indicates that this variant results in a loss of function of the Idh1 protein. However, the specific amino acid change has not been identified.
IDH1 mutant unknown unknown IDH1 mutant indicates an unspecified mutation in the IDH1 gene.
IDH1 over exp none no effect IDH1 over exp indicates an over expression of the Idh1 protein. However, the mechanism causing the over expression is unspecified.
IDH1 R100X missense unknown IDH1 R100X indicates any Idh1 missense mutation that results in replacement of the arginine (R) at amino acid 100 by a different amino acid.
IDH1 wild-type none no effect Wild-type IDH1 indicates that no mutation has been detected within the IDH1 gene.
IDH1 Y139X missense unknown IDH1 Y139X indicates any Idh1 missense mutation that results in replacement of the tyrosine (Y) at amino acid 139 by a different amino acid.
IDH2 act mut unknown gain of function IDH2 act mut indicates that this variant results in a gain of function in the Idh2 protein. However, the specific amino acid change has not been identified.
IDH2 amp none no effect IDH2 amp indicates an increased number of copies of the Idh2 gene. However, the mechanism causing the increase is unspecified.
IDH2 del deletion loss of function IDH2 del indicates a deletion of the IDH2 gene.
IDH2 inact mut unknown loss of function IDH2 inact mut indicates that this variant results in a loss of function of the Idh2 protein. However, the specific amino acid change has not been identified.
IDH2 mutant unknown unknown IDH2 mutant indicates an unspecified mutation in the IDH2 gene.
IDH2 over exp none no effect IDH2 over exp indicates an over expression of the Idh2 protein. However, the mechanism causing the over expression is unspecified.
IDH2 wild-type none no effect Wild-type IDH2 indicates that no mutation has been detected within the IDH2 gene.
JAK1 act mut unknown gain of function JAK1 act mut indicates that this variant results in a gain of function in the Jak1 protein. However, the specific amino acid change has not been identified.
JAK1 amp none no effect JAK1 amplification indicates an increased number of copies of the JAK1 gene. However, the mechanism causing the increase is unspecified.
JAK1 dec exp none no effect JAK1 dec exp indicates decreased expression of the Jak1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
JAK1 del deletion loss of function JAK1 del indicates a deletion of the JAK1 gene.
JAK1 inact mut unknown loss of function JAK1 inact mut indicates that this variant results in a loss of function of the Jak1 protein. However, the specific amino acid change has not been identified.
JAK1 mutant unknown unknown JAK1 mutant indicates an unspecified mutation in the JAK1 gene.
JAK1 positive unknown unknown JAK1 positive indicates the presence of the KIT gene, mRNA, and/or protein.
JAK1 rearrange unknown unknown JAK1 rearrangement indicates an unspecified rearrangement of the JAK1 gene.
JAK1 wild-type none no effect Wild-type JAK1 indicates that no mutation has been detected within the JAK1 gene.
JAK2 act mut unknown gain of function JAK2 act mut indicates that this variant results in a gain of function in the Jak2 protein. However, the specific amino acid change has not been identified.
JAK2 amp none no effect JAK2 amp indicates an increased number of copies of the JAK2 gene. However, the mechanism causing the increase is unspecified.
JAK2 dec exp none no effect JAK2 dec exp indicates decreased expression of the Jak2 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
JAK2 del deletion loss of function JAK2 del indicates a deletion of the JAK2 gene.
JAK2 exon12 unknown unknown JAK2 exon 12 indicates an unspecified mutation has occurred in exon 12 (amino acids 505-547) of the JAK2 gene.
JAK2 fusion fusion unknown JAK2 fusion indicates a fusion of the JAK2 gene, but the fusion partner is unknown.
JAK2 inact mut unknown loss of function JAK2 inact mut indicates that this variant results in a loss of function of the Jak2 protein. However, the specific amino acid change has not been identified.
JAK2 LOH deletion unknown JAK2 LOH indicates the loss of one parental copy of the JAK2 gene, resulting in the loss of heterozygosity.
JAK2 loss unknown loss of function JAK2 loss indicates loss of the JAK2 gene, mRNA, and protein.
JAK2 mutant unknown unknown JAK2 mutant indicates an unspecified mutation in the JAK2 gene.
JAK2 over exp none no effect JAK2 over exp indicates an over expression of the Jak2 protein. However, the mechanism causing the over expression is unspecified.
JAK2 rearrange unknown unknown JAK2 rearrange indicates an unspecified rearrangement of the JAK2 gene.
JAK2 wild-type none no effect Wild-type JAK2 indicates that no mutation has been detected within the JAK2 gene.
JAK3 act mut unknown gain of function JAK3 act mut indicates that this variant results in a gain of function in the Jak3 protein. However, the specific amino acid change has not been identified.
JAK3 inact mut unknown loss of function JAK3 inact mut indicates that this variant results in a loss of function of the Jak3 protein. However, the specific amino acid change has not been identified.
JAK3 mutant unknown unknown JAK3 mutant indicates an unspecified mutation in the JAK3 gene.
JAK3 rearrange unknown unknown JAK3 rearrangement indicates an unspecified rearrangement of the JAK3 gene.
JAK3 wild-type none no effect Wild-type JAK3 indicates that no mutation has been detected within the JAK3 gene.
KEAP1 dec exp none no effect KEAP1 dec exp indicates decreased expression of the Keap1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
KEAP1 inact mut unknown loss of function KEAP1 inact mut indicates that this variant results in a loss of function of the Keap1 protein. However, the specific amino acid change has not been identified.
KEAP1 loss unknown loss of function KEAP1 loss indicates loss of the KEAP1 gene, mRNA, and protein.
KEAP1 mutant unknown unknown KEAP1 mutant indicates an unspecified mutation in the KEAP1 gene.
KEAP1 wild-type none no effect Wild-type KEAP1 indicates that no mutation has been detected within the KEAP1 gene.
KIT act mut unknown gain of function KIT act mut indicates that this variant results in a gain of function in the Kit protein. However, the specific amino acid change has not been identified.
KIT amp none no effect KIT amp indicates an increased number of copies of the KIT gene. However, the mechanism causing the increase is unspecified.
KIT D816X missense unknown KIT D816X indicates any Kit missense mutation that results in the replacement of the aspartic acid (D) at amino acid 816 by a different amino acid.
KIT exon11 unknown unknown KIT exon 11 (amino acids 550-592) indicates an unspecified mutation within the juxtamembrane domain has occurred in exon 11 of the KIT gene.
KIT exon13 unknown unknown KIT exon 13 (amino acids 627-664) indicates an unspecified mutation has occurred in exon 13 of the KIT gene.
KIT exon14 unknown unknown KIT exon 14 (amino acids 664-713) indicates an unspecified mutation has occurred in exon 14 of the KIT gene.
KIT exon17 unknown unknown KIT exon 17 (amino acids 788-828) indicates an unspecified mutation has occurred in exon 17 of the KIT gene.
KIT exon18 unknown unknown KIT exon 18 (amino acids 829-866) indicates an unspecified mutation has occurred in exon 18 of the KIT gene.
KIT exon8 unknown unknown KIT exon 8 (amino acids 411-449) indicates an unspecified mutation has occurred in exon 8 of the KIT gene.
KIT exon9 unknown unknown KIT exon 9 (amino acids 449-514) indicates an unspecified mutation has occurred in exon 9 of the KIT gene.
KIT fusion fusion unknown KIT fusion indicates a fusion of the KIT gene, but the fusion partner is unknown.
KIT mutant unknown unknown KIT mutant indicates an unspecified mutation in the KIT gene.
KIT negative unknown loss of function KIT negative indicates a lack of expression of the KIT mRNA and/or protein.
KIT over exp none no effect KIT over exp indicates an over expression of the KIT protein. However, the mechanism causing the over expression is unspecified.
KIT positive unknown unknown KIT positive indicates the presence of the KIT gene, mRNA, and/or protein.
KIT rearrange unknown unknown KIT rearrangement indicates an unspecified rearrangement of the KIT gene.
KIT V559X missense unknown KIT V559X indicates any Kit missense mutation that results in the replacement of the valine (V) at amino acid 559 by a different amino acid.
KIT wild-type none no effect Wild-type KIT indicates that no mutation has been detected within the KIT gene.
KMT2A act mut unknown gain of function KMT2A act mut indicates that this variant results in a gain of function in the Kmt2a protein. However, the specific amino acid change has not been identified.
KMT2A amp none no effect KMT2A amplification indicates an increased number of copies of the KMT2A gene. However, the mechanism causing the increase is unspecified.
KMT2A fusion fusion unknown KMT2A fusion indicates a fusion of the KMT2A gene, but the fusion partner is unknown.
KMT2A inact mut unknown loss of function KMT2A inact mut indicates that this variant results in a loss of function of the Kmt2a protein. However, the specific amino acid change has not been identified.
KMT2A mutant unknown unknown KMT2A mutant indicates an unspecified mutation in the KMT2A gene.
KMT2A over exp none no effect KMT2A over exp indicates an over expression of the Kmt2a protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
KMT2A positive unknown unknown KMT2A positive indicates the presence of the KMT2A gene, mRNA, and/or protein.
KMT2A rearrange unknown unknown KMT2A rearrangement indicates an unspecified rearrangement of the KMT2A gene.
MAP2K1 act mut unknown gain of function MAP2K1 act mut indicates that this variant results in a gain of function in the Map2k1 protein. However, the specific amino acid change has not been identified.
MAP2K1 amp none no effect MAP2K1 amp indicates an increased number of copies of the MAP2K1 gene. However, the mechanism causing the increase is unspecified.
MAP2K1 fusion fusion unknown MAP2K1 fusion indicates a fusion of the MAP2K1 gene, but the fusion partner is unknown.
MAP2K1 inact mut unknown loss of function MAP2K1 inact mut indicates that this variant results in a loss of function of the Map2k1 protein. However, the specific amino acid change has not been identified.
MAP2K1 mutant unknown unknown MAP2K1 mutant indicates an unspecified mutation in the MAP2K1 gene.
MAP2K1 wild-type none no effect Wild-type MAP2K1 indicates that no mutation has been detected within the MAP2K1 gene.
MDM2 act mut unknown gain of function MDM2 act mut indicates that this variant results in a gain of function in the Mdm2 protein. However, the specific amino acid change has not been identified.
MDM2 amp none no effect MDM2 amp indicates an increased number of copies of the MDM2 gene. However, the mechanism causing the increase is unspecified.
MDM2 inact mut unknown loss of function MDM2 inact mut indicates that this variant results in a loss of function of the Mdm2 protein. However, the specific amino acid change has not been identified.
MDM2 mutant unknown unknown MDM2 mutant indicates an unspecified mutation in the MDM2 gene.
MDM2 negative unknown loss of function MDM2 negative indicates a lack of expression of the MDM2 mRNA and/or protein.
MDM2 over exp none no effect MDM2 over exp indicates an over expression of the Mdm2 protein. However, the mechanism causing the over expression is unspecified.
MDM2 positive unknown unknown MDM2 positive indicates the presence of the MDM2 gene, mRNA, and/or protein.
MDM2 wild-type none no effect Wild-type MDM2 indicates that no mutation has been detected within the MDM2 gene.
MLH1 del deletion loss of function MLH1 del indicates a deletion of the MLH1 gene.
MLH1 del exon4 deletion unknown MLH1 del exon4 indicates a deletion of exon 4 of the MLH1 gene.
MLH1 del exon5 deletion unknown MLH1 del exon5 indicates a deletion of exon 5 of the MLH1 gene.
MLH1 hypermethylation unknown unknown MLH1 hypermethylation indicates an increased methylation of the MLH1 gene. However, the mechanism causing the hypermethylation is unspecified.
MLH1 inact mut unknown loss of function MLH1 inact mut indicates that this variant results in a loss of function of the Mlh1 protein. However, the specific amino acid change has not been identified.
MLH1 LOH deletion unknown MLH1 LOH indicates the loss of one parental copy of the MLH1 gene, resulting in loss of heterozygosity.
MLH1 loss unknown loss of function MLH1 loss indicates loss of the MLH1 gene, mRNA, and protein.
MLH1 mutant unknown unknown MLH1 mutant indicates an unspecified mutation in the MLH1 gene.
MLH1 negative unknown loss of function MLH1 negative indicates a lack of expression of the MLH1 mRNA and/or protein.
MLH1 positive unknown unknown MLH1 positive indicates the presence of the MLH1 gene, mRNA, and/or protein.
MSH2 hypermethylation unknown unknown MSH2 hypermethylation indicates an increased methylation of the MSH2 gene. However, the mechanism causing the hypermethylation is unspecified.
MSH2 inact mut unknown loss of function MSH2 inact mut indicates that this variant results in a loss of function of the Msh2 protein. However, the specific amino acid change has not been identified.
MSH2 loss unknown loss of function MSH2 loss indicates loss of the MSH2 gene, mRNA, and protein.
MSH2 mutant unknown unknown MSH2 mutant indicates an unspecified mutation in the MSH2 gene.
MSH2 negative unknown loss of function MSH2 negative indicates a lack of expression of the MSH2 mRNA and/or protein.
MSH2 positive unknown unknown MSH2 positive indicates the presence of the MSH2 gene, mRNA, and/or protein.
MSH2 wild-type none no effect Wild-type MSH2 indicates that no mutation has been detected within the MSH2 gene.
MSH3 inact mut unknown loss of function MSH3 inact mut indicates that this variant results in a loss of function of the Msh3 protein. However, the specific amino acid change has not been identified.
MSH3 loss unknown loss of function MSH3 loss indicates loss of the MSH3 gene, mRNA, and protein.
MSH3 mutant unknown unknown MSH3 mutant indicates an unspecified mutation in the MSH3 gene.
MSH6 amp none no effect MSH6 amplification indicates an increased number of copies of the MSH6 gene. However, the mechanism causing the increase is unspecified.
MSH6 hypermethylation unknown unknown MSH6 hypermethylation indicates an increased methylation of the MSH6 gene. However, the mechanism causing the hypermethylation is unspecified.
MSH6 inact mut unknown loss of function MSH6 inact mut indicates that this variant results in a loss of function of the Msh6 protein. However, the specific amino acid change has not been identified.
MSH6 loss unknown loss of function MSH6 loss indicates loss of the MSH6 gene, mRNA, and protein.
MSH6 mutant unknown unknown MSH6 mutant indicates an unspecified mutation in the MSH6 gene.
MSH6 negative unknown loss of function MSH6 negative indicates a lack of expression of the MSH6 mRNA and/or protein.
MSH6 positive unknown unknown MSH6 positive indicates the presence of the MSH6 gene, mRNA, and/or protein.
NRAS A146X missense unknown NRAS A146X indicates any NRAS missense mutation that results in replacement of the alanine (A) at amino acid 146 by a different amino acid.
NRAS A59X missense unknown NRAS A59X indicates any NRAS missense mutation that results in the replacement of the alanine (A) at amino acid 59 by a different amino acid.
NRAS act mut unknown unknown NRAS act mut indicates that the variant results in activation of NRAS downstream signaling. The mechanism causing the activation can include either loss of GTP hydrolysis activity (loss of function) or increased nucleotide exchange rate (gain of function).
NRAS amp none no effect NRAS amplification indicates an increased number of copies of the NRAS gene. However, the mechanism causing the increase is unspecified.
NRAS dec exp none no effect NRAS dec exp indicates decreased expression of the Nras protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
NRAS exon2 unknown unknown NRAS exon 2 indicates an unspecified mutation has occurred in exon 2 of the NRAS gene.
NRAS exon3 unknown unknown NRAS exon 3 indicates an unspecified mutation has occurred in exon 3 of the NRAS gene.
NRAS exon4 unknown unknown NRAS exon 4 indicates an unspecified mutation has occurred in exon 4 of the NRAS gene.
NRAS inact mut unknown loss of function NRAS inact mut indicates that the variant results in failure to activate NRAS downstream signaling. However, the specific amino acid change has not been identified.
NRAS K117X missense unknown NRAS K117X indicates any NRAS missense mutation that results in the replacement of the lysine (K) at amino acid 117 by a different amino acid.
NRAS mutant unknown unknown NRAS mutant indicates an unspecified mutation in the NRAS gene.
NRAS over exp none no effect NRAS over exp indicates an over expression of the Nras protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
NRAS positive unknown unknown NRAS positive indicates the presence of the NRAS gene, mRNA, and/or protein.
NRAS wild-type none no effect Wild-type NRAS indicates that no mutation has been detected within the NRAS gene.
PBRM1 del deletion loss of function PBRM1 del indicates a deletion of the PBRM1 gene.
PBRM1 inact mut unknown loss of function PBRM1 inact mut indicates that this variant results in a loss of function of the Pbrm1 protein. However, the specific amino acid change has not been identified.
PBRM1 loss unknown loss of function PBRM1 loss indicates loss of the PBRM1 gene, mRNA, and protein.
PBRM1 mutant unknown unknown PBRM1 mutant indicates an unspecified mutation in the PBRM1 gene.
PIK3CA act mut unknown gain of function PIK3CA act mut indicates that this variant results in a gain of function in the Pik3ca protein. However, the specific amino acid change has not been identified.
PIK3CA amp none no effect PIK3CA amplification indicates an increased number of copies of the PIK3CA gene. However, the mechanism causing the increase is unspecified.
PIK3CA dec exp none no effect PIK3CA dec exp indicates decreased expression of the Pik3ca protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
PIK3CA E542X missense unknown PIK3CA E542X indicates any Pik3ca missense mutation that results in the replacement of the glutamic acid (E) at amino acid 542 by a different amino acid.
PIK3CA exon10 unknown unknown PIK3CA exon 10 indicates an unspecified mutation has occurred in exon 10 (corresponding to amino acids 514 to 555) of the PIK3CA gene. PIK3CA exon 10 is sometimes reported as exon 9, when only coding exons are considered in numbering.
PIK3CA exon20 unknown unknown PIK3CA exon 20 indicates an unspecified mutation has occurred in exon 20 (corresponding to amino acids 929 to 979) of the PIK3CA gene. PIK3CA exon 21 (corresponding to amino acids 979 to 1068) is sometimes reported as exon 20, when only coding exons are considered in numbering.
PIK3CA exon21 unknown unknown PIK3CA exon 21 indicates an unspecified mutation has occurred in exon 21 (corresponding to amino acids 979 to 1068) of the PIK3CA gene. PIK3CA exon 21 is sometimes reported as exon 20, when only coding exons are considered in numbering.
PIK3CA exon5 unknown unknown PIK3CA exon 5 indicates an unspecified mutation has occurred in exon 5 (corresponding to amino acids 272 to 353) of the PIK3CA gene. PIK3CA exon 5 is sometimes reported as exon 4, when only coding exons are considered in numbering.
PIK3CA exon8 unknown unknown PIK3CA exon 8 indicates an unspecified mutation has occurred in exon 8 (corresponding to amino acids 418 to 468) of the PIK3CA gene. PIK3CA exon 8 is sometimes reported as exon 7, when only coding exons are considered in numbering.
PIK3CA exon9 unknown unknown PIK3CA exon 9 indicates an unspecified mutation has occurred in exon 9 (corresponding to amino acids 469 to 513) of the PIK3CA gene. PIK3CA exon 10 (corresponding to amino acids 514 to 555) is sometimes reported as exon 9, when only coding exons are considered in numbering.
PIK3CA inact mut unknown loss of function PIK3CA inact mut indicates that this variant results in a loss of function of the Pik3ca protein. However, the specific amino acid change has not been identified.
PIK3CA mutant unknown unknown PIK3CA mutant indicates an unspecified mutation within the PIK3CA gene.
PIK3CA over exp none no effect PIK3CA over exp indicates an over expression of the Pik3ca protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
PIK3CA positive unknown unknown PIK3CA positive indicates the presence of the PIK3CA gene, mRNA and/or protein.
PIK3CA Q546X missense unknown PIK3CA Q546X indicates any PIK3CA missense mutation that results in replacement of the glutamine (Q) at amino acid 546 by a different amino acid.
PIK3CA wild-type none no effect Wild-type PIK3CA indicates that no mutation has been detected within the PIK3CA gene.
PMS2 hypermethylation unknown unknown PMS2 hypermethylation indicates an increased methylation of the PMS2 gene. However, the mechanism causing the hypermethylation is unspecified.
PMS2 inact mut unknown loss of function PMS2 inact mut indicates that this variant results in a loss of function of the Pms2 protein. However, the specific amino acid change has not been identified.
PMS2 loss unknown loss of function PMS2 loss indicates loss of the PMS2 gene, mRNA, and protein.
PMS2 mutant unknown unknown PMS2 mutant indicates an unspecified mutation in the PMS2 gene.
PMS2 negative unknown loss of function PMS2 negative indicates a lack of the PMS2 gene, mRNA, and/or protein.
PMS2 positive unknown unknown PMS2 positive indicates the presence of the PMS2 gene, mRNA, and/or protein.
POLD1 inact mut unknown loss of function POLD1 inact mut indicates that this variant results in a loss of function of the Pold1 protein. However, the specific amino acid change has not been identified.
POLD1 mutant unknown unknown POLD1 mutant indicates an unspecified mutation in the POLD1 gene.
POLE inact mut unknown loss of function POLE inact mut indicates that this variant results in a loss of function of the Pole protein. However, the specific amino acid change has not been identified.
POLE mutant unknown unknown POLE mutant indicates an unspecified mutation in the POLE gene.
POLE wild-type none no effect Wild-type POLE indicates that no mutation has been detected within the POLE gene.
PTEN dec exp none no effect PTEN dec exp indicates decreased expression of the Pten protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
PTEN del deletion loss of function PTEN del indicates a deletion of the PTEN gene.
PTEN fusion fusion unknown PTEN fusion indicates a fusion of the PTEN gene, but the fusion partner is unknown.
PTEN inact mut unknown loss of function PTEN inact mut indicates that this variant results in a loss of function of the Pten protein. However, the specific amino acid change has not been identified.
PTEN LOH deletion unknown PTEN LOH indicates the loss of one parental copy of the PTEN gene, resulting in loss of heterozygosity.
PTEN loss unknown loss of function PTEN loss indicates a loss of the PTEN gene, mRNA, and protein, which leads to suppression of Ar-dependent gene expression (PMID: 21620777), epithelial-mesenchymal transition in cell culture (PMID: 20032390), and promotes KRAS-dependent tumor formation (PMID: 20807812), and decreased apoptosis and increased cell survival in a mouse model (PMID: 12782594). PTEN loss has been identified in a number of cancers (PMID: 30738865), including prostate cancer (PMID: 29460925) and glioblastoma (PMID: 9331071).
PTEN mutant unknown unknown PTEN mutant indicates an unspecified mutation in the PTEN gene.
PTEN negative unknown loss of function PTEN negative indicates a lack of the PTEN gene, mRNA, and/or protein.
PTEN over exp none no effect PTEN over exp indicates an over expression of the Pten protein. However, the mechanism causing the over expression is unspecified.
PTEN positive unknown unknown PTEN positive indicates the presence of the PTEN gene, mRNA, and/or protein.
PTEN wild-type none no effect Wild-type PTEN indicates that no mutation has been detected within the PTEN gene.
RB1 dec exp none no effect RB1 dec exp indicates decreased expression of the Rb1 protein and/or mRNA. However, the mechanism causing the decrease is unspecified.
RB1 del deletion loss of function RB1 del indicates a deletion of the RB1 gene.
RB1 inact mut unknown loss of function RB1 inact mut indicates that this variant results in a loss of function of the Rb1 protein. However, the specific amino acid change has not been identified.
RB1 loss unknown loss of function RB1 loss indicates loss of the RB1 gene, mRNA, and protein.
RB1 mutant unknown unknown RB1 mutant indicates an unspecified mutation in the RB1 gene.
RB1 negative unknown loss of function RB1 negative indicates a lack of the RB1 gene, mRNA, and/or protein.
RB1 positive unknown unknown RB1 positive indicates the presence of the RB1 gene, mRNA, and/or protein.
RB1 wild-type none no effect Wild-type RB1 indicates that no mutations have been detected within the RB1 gene.
RET A883X missense unknown RET A883X indicates any Ret missense mutation that results in replacement of the alanine (A) at amino acid 883 by a different amino acid.
RET act mut unknown gain of function RET act mut indicates that this variant results in a gain of function in the Ret protein. However the specific amino acid change has not been identified.
RET amp none no effect RET amp indicates an increased number of copies of the RET gene. However, the mechanism causing the increase is unspecified.
RET C609X missense unknown RET C609X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 609 by a different amino acid.
RET C611X missense unknown RET C611X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 611 by a different amino acid.
RET C618X missense unknown RET C618X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 618 by a different amino acid.
RET C620X missense unknown RET C620X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 620 by a different amino acid.
RET C630X missense unknown RET C630X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 630 by a different amino acid.
RET C634X missense unknown RET C634X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 634 by a different amino acid.
RET E768X missense unknown RET E768X indicates any Ret missense mutation that results in replacement of the glutamic acid (E) at amino acid 768 by a different amino acid.
RET fusion fusion unknown RET fusion indicates a fusion of the RET gene, but the fusion partner is unknown.
RET inact mut unknown loss of function RET inact mut indicates that this variant results in a loss of function of the Ret protein. However, the specific amino acid change has not been identified.
RET L790X missense unknown RET L790X indicates any Ret missense mutation that results in replacement of the leucine (L) at amino acid 790 by a different amino acid.
RET M918X missense unknown RET M918X indicates any Ret missense mutation that results in replacement of the methionine (M) at amino acid 918 by a different amino acid.
RET mutant unknown unknown RET mutant indicates an unspecified mutation in the RET gene.
RET over exp none no effect RET over exp indicates an over expression of the Ret protein. However, the mechanism causing the over expression is unspecified.
RET positive unknown unknown RET positive indicates the presence of the RET gene, mRNA, and/or protein.
RET rearrange unknown unknown RET rearrangement indicates an unspecified rearrangement of the RET gene.
RET S891X missense unknown RET S891X indicates any Ret missense mutation that results in replacement of the serine (S) at amino acid 891 by a different amino acid.
RET V804X missense unknown RET V804X indicates any Ret missense mutation that results in replacement of the valine (V) at amino acid 804 by a different amino acid.
RET wild-type none no effect Wild-type RET indicates that no mutation has been detected within the RET gene.
RET Y791X missense unknown RET Y791X indicates any Ret missense mutation that results in replacement of the tyrosine (Y) at amino acid 791 by a different amino acid.
ROS1 act mut unknown gain of function ROS1 act mut indicates that this variant results in a gain of function in the Ros1 protein. However, the specific amino acid change has not been identified.
ROS1 amp none no effect ROS1 amplification indicates an increased number of copies of the ROS1 gene. However, the mechanism causing the increase is unspecified.
ROS1 dec exp none no effect ROS1 dec exp indicates decreased expression of the Ros1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
ROS1 del deletion loss of function ROS1 del indicates a deletion of the ROS1 gene.
ROS1 fusion fusion unknown ROS1 fusion indicates a fusion of the ROS1 gene, but the fusion partner is unknown.
ROS1 inact mut unknown loss of function ROS1 inact mut indicates that this variant results in a loss of function of the Ros1 protein. However, the specific amino acid change has not been identified.
ROS1 mutant unknown unknown ROS1 mutant indicates an unspecified mutation in the ROS1 gene.
ROS1 negative unknown loss of function ROS1 negative indicates a lack of the ROS1 gene, mRNA, and/or protein.
ROS1 positive unknown unknown ROS1 positive indicates the presence of the ROS1 gene, mRNA, and/or protein. ROS1 positive has been used alternatively to refer to presence of a ROS1 fusion or rearrangement. For related data, refer to ROS1 fusion or ROS1 rearrange in CKB.
ROS1 rearrange unknown unknown ROS1 rearrange indicates an unspecified rearrangement of the ROS1 gene.
ROS1 wild-type none no effect Wild-type ROS1 indicates that no mutation has been detected within the ROS1 gene.
STK11 amp none no effect STK11 amplification indicates an increased number of copies of the STK11 gene. However, the mechanism causing the increase is unspecified.
STK11 dec exp none no effect STK11 dec exp indicates decreased expression of the Stk11 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified
STK11 del deletion loss of function STK11 del indicates a deletion of the STK11 gene.
STK11 inact mut unknown loss of function STK11 inact mut indicates that this variant results in a loss of function of the Stk11 protein. However, the specific amino acid change has not been identified.
STK11 loss unknown loss of function STK11 loss indicates loss of the STK11 gene, mRNA, and protein.
STK11 mutant unknown unknown STK11 mutant indicates an unspecified mutation in the STK11 gene.
STK11 negative unknown loss of function STK11 negative indicates a lack of the STK11 gene, mRNA, and/or protein
STK11 wild-type none no effect Wild-type STK11 indicates that no mutation has been detected within the STK11 gene.
TET2 del deletion loss of function TET2 del indicates a deletion of the TET2 gene.
TET2 inact mut unknown loss of function TET2 inact mut indicates that this variant results in a loss of Tet2 protein function. However, the specific amino acid change has not been identified.
TET2 loss unknown loss of function TET2 loss indicates loss of the TET2 gene, mRNA, and protein.
TET2 mutant unknown unknown TET2 mutant indicates an unspecified mutation in the TET2 gene.
TET2 wild-type none no effect Wild-type TET2 indicates that no mutations have been detected within the TET2 gene.
TP53 act mut unknown gain of function TP53 act mut indicates that this variant results in a gain of function in the Tp53 protein. However, the specific amino acid change has not been identified.
TP53 amp none no effect TP53 amp indicates an increased number of copies of the TP53 gene. However, the mechanism causing the increase is unspecified.
TP53 dec exp none no effect TP53 dec exp indicates decreased expression of the Tp53 protein. However, the mechanism causing the decreased expression is unspecified.
TP53 del deletion loss of function TP53 del indicates a deletion of the TP53 gene.
TP53 exon10 unknown unknown TP53 exon 10 indicates an unspecified mutation has occurred in exon 10 of the TP53 gene.
TP53 exon11 unknown unknown TP53 exon 11 indicates an unspecified mutation has occurred in exon 11 of the TP53 gene.
TP53 exon2 unknown unknown TP53 exon 2 indicates an unspecified mutation has occurred in exon 2 of the TP53 gene.
TP53 exon4 unknown unknown TP53 exon 4 indicates an unspecified mutation has occurred in exon 4 of the TP53 gene.
TP53 exon5 unknown unknown TP53 exon 5 indicates an unspecified mutation has occurred in exon 5 of the TP53 gene.
TP53 exon6 unknown unknown TP53 exon 6 indicates an unspecified mutation has occurred in exon 6 of the TP53 gene.
TP53 exon7 unknown unknown TP53 exon 7 indicates an unspecified mutation has occurred in exon 7 of the TP53 gene.
TP53 exon8 unknown unknown TP53 exon 8 indicates an unspecified mutation has occurred in exon 8 of the TP53 gene.
TP53 exon9 unknown unknown TP53 exon 9 indicates an unspecified mutation has occurred in exon 9 of the TP53 gene.
TP53 inact mut unknown loss of function TP53 inact mut indicates that this variant results in a loss of function of the Tp53 protein. However, the specific amino acid change has not been identified.
TP53 loss unknown loss of function TP53 loss indicates loss of the TP53 gene, mRNA, and protein.
TP53 mutant unknown unknown TP53 mutant indicates an unspecified mutation within the TP53 gene.
TP53 negative unknown loss of function TP53 negative indicates a lack of the TP53 gene, mRNA, and/or protein.
TP53 over exp none no effect TP53 over exp indicates an over expression of the Tp53 protein. However, the mechanism causing the over expression is unspecified.
TP53 positive unknown unknown TP53 positive indicates the presence of the TP53 gene, mRNA, and/or protein.
TP53 R175X missense unknown TP53 R175X indicates a hotspot mutation resulting in an amino acid change at codon 175 of the Tp53 protein, which often results in a loss of Tp53 protein function.
TP53 R273X missense unknown TP53 R273X indicates a hotspot mutation resulting in an amino acid change at codon 273 of the Tp53 protein, which often results in a loss of Tp53 protein function.
TP53 wild-type none no effect Wild-type TP53 indicates that no mutation has been detected within the TP53 gene.
VHL amp none no effect VHL amplification indicates an increased number of copies of the VHL gene. However, the mechanism causing the increase is unspecified.
VHL del deletion loss of function VHL del indicates a deletion of the VHL gene.
VHL inact mut unknown loss of function VHL inact mut indicates that this variant results in a loss of function of the Vhl protein. However, the specific amino acid change has not been identified.
VHL loss unknown loss of function VHL loss indicates loss of the VHL gene, mRNA and protein.
VHL mutant unknown unknown VHL mutant indicates an unspecified mutation in the VHL gene.
VHL negative unknown loss of function VHL negative indicates a lack of the VHL gene, mRNA, and/or protein.
VHL over exp none no effect VHL over exp indicates an over expression of the Vhl protein. However, the mechanism causing the over expression is unspecified.
VHL wild-type none no effect Wild-type VHL indicates that no mutation has been detected within the VHL gene.
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References